Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 36
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sex Differences in Motor and Non-Motor Symptoms among Spanish Patients with Parkinson's Disease

  • Santos García, Diego|||0000-0002-3126-5111
  • Laguna, Ariadna|||0000-0002-9732-6677
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • de Deus Fonticoba, Teresa
  • Cores Bartolomé, Carlos|||0000-0002-8352-2263
  • Feal Painceiras, Maria J.
  • Íñiguez Alvarado, María Cristina
  • García Díaz, Iago|||0000-0003-3304-0714
  • Jesús, Silvia
  • Boungiorno, M. T.
  • Planellas, Lluis|||0000-0002-0769-6675
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • López Manzanares, Lydia|||0000-0003-4615-4542
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Ávila Rivera, Maria A.
  • Gómez Mayordomo, Víctor|||0000-0001-9343-8439
  • Nogueira, Víctor
  • Puente, Víctor
  • Dotor García-Soto, Julio
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Carrillo Padilla, Francisco
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, Maria G.
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Gastón, Itziar
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Mendez-Gonzalez, Manuel|||0000-0002-5218-0774
  • Seijo, Manuel
  • Rúiz Martínez, Javier
  • Valero, Caridad
  • Kurtis, Mónica|||0000-0003-3037-9712
  • González Ardura, Jessica
  • Alonso Redondo, Ruben
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • López Díaz, Luis M.
  • McAfee, Darrian
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Mir, Pablo|||0000-0003-1656-302X
Sex plays a role in Parkinson's disease (PD) mechanisms. We analyzed sex difference manifestations among Spanish patients with PD. PD patients who were recruited from the Spanish cohort COPPADIS from January 2016 to November 2017 were included. A cross-sectional and a two-year follow-up analysis were conducted. Univariate analyses and general linear model repeated measure were used. At baseline, data from 681 PD patients (mean age 62.54 ± 8.93) fit the criteria for analysis. Of them, 410 (60.2%) were males and 271 (39.8%) females. There were no differences between the groups in mean age (62.36 ± 8.73 vs. 62.8 ± 9.24; p = 0.297) or in the time from symptoms onset (5.66 ± 4.65 vs. 5.21 ± 4.11; p = 0.259). Symptoms such as depression (p < 0.0001), fatigue (p < 0.0001), and pain (p < 0.00001) were more frequent and/or severe in females, whereas other symptoms such as hypomimia (p < 0.0001), speech problems (p < 0.0001), rigidity (p < 0.0001), and hypersexuality (p < 0.0001) were more noted in males. Women received a lower levodopa equivalent daily dose (p = 0.002). Perception of quality of life was generally worse in females (PDQ-39, p = 0.002; EUROHIS-QOL8, p = 0.009). After the two-year follow-up, the NMS burden (Non-Motor Symptoms Scale total score) increased more significantly in males (p = 0.012) but the functional capacity (Schwab and England Activities of Daily Living Scale) was more impaired in females (p = 0.001). Conclusion: The present study demonstrates that there are important sex differences in PD. Long-term prospective comparative studies are needed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Changes in Principal Caregiver Mood Affects the Mood of the Parkinson's Disease Patient, The Vicious Cycle of Illness

  • Santos García, Diego|||0000-0002-3126-5111
  • de Deus Fonticoba, Teresa
  • Cores Bartolomé, Carlos|||0000-0002-8352-2263
  • Feal Painceiras, Maria J.
  • Íñiguez Alvarado, María Cristina
  • García Díaz, Iago|||0000-0003-3304-0714
  • Jesús, Silvia
  • Buongiorno, Maria Teresa
  • Planellas, Lluis|||0000-0002-0769-6675
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • López Manzanares, Lydia|||0000-0003-4615-4542
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Ávila Rivera, Maria A.
  • Gómez Mayordomo, Víctor|||0000-0001-9343-8439
  • Nogueira, Víctor
  • Puente, Víctor
  • Dotor García-Soto, Julio
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Carrillo Padilla, Francisco
  • Martínez Castrillo, Juan C.
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, Maria G.
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Gastón, Itziar
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Menéndez González, Manuel
  • Seijo, Manuel
  • Rúiz Martínez, J.
  • Valero, Caridad
  • Kurtis, Mónica|||0000-0003-3037-9712
  • González Ardura, Javier
  • Alonso Redondo, Ruben
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • López Díaz, Luis M.
  • McAfee, Darrian
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Mir, Pablo|||0000-0003-1656-302X
Although many studies have analyzed what factors contribute to caregiver burden in Parkinson's disease (PD), there is currently no knowledge about how the status of the caregiver could impact the patient. Objective: The aim of this study was to analyze how the change in the caregiver's status influences PD patients. PD patients and their caregivers who were recruited from January/2016 to November/2017 from 35 centers in Spain from the COPPADIS cohort were included in the study (V0). They were evaluated again at 2-year follow-up (V2). Caregivers completed the Zarit Caregiver Burden Inventory (ZCBI), Caregiver Strain Index (CSI), Beck Depression Inventory-II (BDI-II), and EUROHIS-QOL 8-item index (EUROHIS-QOL8) at V0 and V2. Multivariate models were used to analyze the impact of the change from V0 to V2 () on the caregiver's status over the change in the patient's status. BDI-II and EUROHIS-QOL8 in the caregiver predicted BDI-II (= 0.32; p < 0.0001; R2 = 0.71) and EUROHIS-QOL8 (= 0.39; p < 0.0001; R2 = 0.68) in the patient, respectively. Variables related to the caregiver were not associated with changes in the patient's health-related QoL (PDQ-39 [39-item Parkinson's disease Questionnaire]) or autonomy for activities of daily-living (ADLS [Schwab & England Activities of Daily Living Scale]). The change in the caregiver's mood and global QoL was associated with the change in the patient's mood and global QoL, respectively, independently of other variables of the disease influencing both patient's aspects. Based on this finding, it could be of great importance to detect depression in the principal caregiver of a patient and act on it as earlier as possible.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Falls Predict Acute Hospitalization in Parkinson's Disease

  • Santos García, Diego|||0000-0002-3126-5111
  • de Deus Fonticoba, Teresa
  • Cores, Carlos
  • Suarez Castro, Ester
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Jesús Maestre, Silvia|||0000-0002-1874-4628
  • Mir, Pablo|||0000-0003-1656-302X
  • Cosgaya, Marina
  • Martí Domenech, Maria Josep|||0000-0002-9872-7835
  • Pastor, Pau|||0000-0002-7493-8777
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • Seijo, Manuel
  • Legarda, Inés
  • Vives, Bárbara
  • Caballol, Nuria|||0000-0003-3363-3077
  • Ruiz Martinez, Javier
  • Croitoru, Ioana
  • Cubo, Esther|||0000-0003-0018-1182
  • Miranda, Javier
  • Alonso Losada, Maria Gema
  • Labandeira, Carmen
  • Lopez Ariztegui, Nuria
  • Morales-Casado, Mabel
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Infante, Jon|||0000-0003-4025-4606
  • Escalante, Sonia|||0000-0001-8931-1400
  • Bernardo, Noemí
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Menéndez González, Manuel
  • Garcia Caldentey, Juan
  • Borrue, Carmen
  • Vela, Lydia|||0000-0001-6663-395X
  • Catalán Alonso, Maria José
  • Gomez Mayordomo, Víctor
  • Kurtis, Mónica|||0000-0003-3037-9712
  • Prieto, Cristina|||0000-0002-0812-8100
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • Nogueira, Víctor
  • Lopez Manzanares, Lydia
  • Ávila Rivera, Maria Asunción
  • Puente, Victor
  • García Moreno, José Manuel
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Carrillo Padilla, Francisco
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Gaston, Itziar
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Valero, Caridad
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • González Ardura, Jessica
  • Lopez Diaz, Luis Manuel
  • Martínez Martín, Pablo|||0000-0003-0837-5280
There is a need for identifying risk factors for hospitalization in Parkinson's disease (PD) and also interventions to reduce acute hospital admission. Objective: To analyze the frequency, causes, and predictors of acute hospitalization (AH) in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015) cohort from January 2016 to November 2017, were included in the study. In order to identify predictors of AH, Kaplan-Meier estimates of factors considered as potential predictors were obtained and Cox regression performed on time to hospital encounter 1-year after the baseline visit. Thirty-five out of 605 (5.8%) PD patients (62.5±8.9 years old; 59.8% males) presented an AH during the 1-year follow-up after the baseline visit. Traumatic falls represented the most frequent cause of admission, being 23.7% of all acute hospitalizations. To suffer from motor fluctuations (HR [hazard ratio] 2.461; 95% CI, 1.065-5.678; p = 0.035), a very severe non-motor symptoms burden (HR [hazard ratio] 2.828; 95% CI, 1.319-6.063; p = 0.008), falls (HR 3.966; 95% CI 1.757-8.470; p = 0.001), and dysphagia (HR 2.356; 95% CI 1.124-4.941; p = 0.023) was associated with AH after adjustment to age, gender, disease duration, levodopa equivalent daily dose, total number of non-antiparkinsonian drugs, and UPDRS-IIIOFF. Of the previous variables, only falls (HR 2.998; 95% CI 1.080-8.322; p = 0.035) was an independent predictor of AH. Falls is an independent predictor of AH in PD patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline

  • Rodríguez Antigüedad, Jon|||0000-0002-9316-1772
  • Martínez-Horta, Saul|||0000-0003-0125-7249
  • Puig-Davi, Arnau|||0000-0001-8883-4947
  • Horta-Barba, Andrea|||0000-0003-0050-5466
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • de Deus Fonticoba, Teresa
  • Jesús, Silvia
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Ávila, Asunción|||0000-0001-8357-0751
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • López Manzanares, Lydia|||0000-0003-4615-4542
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Gómez Mayordomo, Víctor|||0000-0001-9343-8439
  • González Ardura, Jessica
  • Dotor García-Soto, Julio
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Mendoza, Zebenzui
  • Pareés, Isabel|||0000-0002-6873-4823
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, María G.
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Gastón, Itziar
  • Ruiz Martínez, Javier|||0000-0001-7326-6270
  • Buongiorno, María Teresa
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • Valero, Caridad
  • Puente, Víctor
  • Kurtis, Mónica|||0000-0003-3037-9712
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Mir, Pablo|||0000-0003-1656-302X
  • Santos García, Diego|||0000-0002-3126-5111
  • Kulisevsky, Jaime|||0000-0003-4870-1431
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Correction to, Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline (Journal of Neurology, (2025), 272, 3, (246), 10.1007/s00415-024-12808-0)

  • Rodríguez Antigüedad, Jon|||0000-0002-9316-1772
  • Martínez-Horta, Saul|||0000-0003-0125-7249
  • Puig-Davi, Arnau|||0000-0001-8883-4947
  • Horta-Barba, Andrea|||0000-0003-0050-5466
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • de Deus Fonticoba, Teresa
  • Jesús Maestre, Silvia|||0000-0002-1874-4628
  • Cosgaya, Marina
  • Garcia Caldentey, Juan
  • Ávila, Asunción|||0000-0001-8357-0751
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • López Manzanares, Lydia|||0000-0003-4615-4542
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Gómez Mayordomo, Víctor|||0000-0001-9343-8439
  • González Ardura, Jessica
  • Dotor García-Soto, Julio
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Mendoza, Zebenzui
  • Pareés, Isabel|||0000-0002-6873-4823
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, Maria G.
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Gastón, Itziar
  • Ruiz Martínez, Javier|||0000-0001-7326-6270
  • Buongiorno, Maria Teresa
  • Valero Mayor, Cristina|||0000-0003-3397-2888
  • Puente, Víctor
  • Kurtis, M.
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Martínez-Martín, P.
  • Mir, Pablo|||0000-0003-1656-302X
  • Santos-García, D.
  • Villanueva, Càndid|||0000-0002-3674-914X
  • Vargas, L.
  • Tartari, J. P.
  • Castro, E.S.
  • Vila, B.S.
  • Peña, M.S.
  • Seijo, Manuel
  • Rodríguez, J.C.S.
  • García, D.S.
  • Santacruz, Pilar
  • Rodríguez, A.S.
  • Díez, G.S.
  • Sánchez-Carpintero, Macarena
  • Alonso, P.S.
  • De Arcos, M.R.
  • Roldán, F.
  • Pérez, A.B.R.
  • Méndez, L.R.
  • Rafales, N.R.
  • Daví, A.P.
  • Morlans, M.P.
  • Jurczynska, C.P.
  • Prats, M.A.
  • Planellas, L.
  • Planas-Ballvé, Anna|||0000-0002-8137-0622
  • Noguera, R.P.
  • Fuertes, A.P.
  • Pastor, P.
  • Pascual-Sedano, B.
  • Ponte, S.N.
  • Amado, A.N.
  • Nogueira, V.
  • García, I.M.
  • Diéguez, A.M.
  • Casado, M.I.M.
  • Santiago, J.M.
  • del Barrio, C.M.
  • González, M.M.
  • Plasencia, Z.M.
  • Meitín, M.T.
  • McAfee, D.
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Castrillo, J.C.M.
  • Martí, M.J.
  • Andres, G.M.
  • Mata, M.
  • Macías, Y.
  • del Pozo, S.L.
  • Seoane, B.L.
  • Manzanares, L.L.
  • Domínguez, D.L.
  • Díaz, L.M.L.
  • Ariztegui, N.L.
  • Gómez, S.L.
  • Castro, M.L.
  • Lacruz, F.
  • Labrador, M.A.
  • Labandeira, C.
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Infante, J.
  • Calderón, D.I.
  • Vara, J.H.
  • Guardia, G.
  • Solá, M.G.
  • Díaz, A.G.
  • Toledo, G.R.G.
  • Palmás, M.J.G.
  • García, B.G.
  • Aloy, J.G.
  • Mayordomo, V.G.
  • Garre, M.P.G.
  • Moreno, J.M.G.
  • Díez, C.G.
  • García Campos, Cristina|||0000-0003-3277-2374
  • Caldentey, J.G.
  • Gallego, Miguel|||0000-0002-8882-4033
  • Gámez, P.
  • Guillán, N.F.
  • Peyret, E.E.
  • Erro, E.
  • García-Soto, J.D.
  • Díez-Fairen, M.
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • Cuevas, A.C.
  • Foraster, A.C.
  • Fernández, A.C.
  • Clavero, P.
  • Catalán, M.J.
  • Casas Díaz, Encarna|||0000-0002-5901-6555
  • Padilla, F.J.C.
  • Carrillo, F.
  • Pendón, E.C.
  • Medina, H.C.
  • Lorenzo, A.C.
  • López, I.C.
  • González, C.C.
  • Botí, M.|||0000-0003-2963-6929
  • Estrada, M.B.
  • Bejr-kasem, Helena|||0000-0001-8828-5976
  • Lambrich, N.B.
  • Ávila, M.A.
  • Aguilar, Mireia
  • Vidondo, A.A.
  • Arribas, Sonia
  • Arnáiz, S.
  • Díaz, A.A.
  • Sauco, M.Á.
  • Álvarez, I.
  • Redondo, R.A.
  • Frech, F.A.
  • Cánovas, A.A.
  • Losada, M.G.A.
  • Almeria, Marta|||0000-0001-7445-6113
  • Adarmes, A.D.
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • Vives, B.
In the original version of this article, abstract was missing and should have read Background Parkinson's Disease (PD)-associated subjective cognitive decline (PDSCD) is defined as cognitive complaints without objective cognitive impairment. Based on most studies, it is associated with a greater risk of cognitive decline and may represent a prodromal stage of cognitive impairment. Methods The main objectives are to identify cognitive progression patterns and clinical predictors of worse cognitive decline within a large PD-SCD cohort with a 4-year follow-up. All patients belong to the prospective observational multicenter study COPPADIS. Results A total of 198 PD-SCD subjects were analyzed. Mean age was 60.9, mean disease duration 5.2, and mean PD-Cognitive Rating Scale (PD-CRS) 97.6. Subjects were classified as Progressors if their Reliable Change Index was ≤ - 1.64 at year 4, and as non-Progressors if it was.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dysphagia in Parkinson's disease. A 5-year follow-up study

  • Santos García, Diego|||0000-0002-3126-5111
  • de Deus Fonticoba, Teresa
  • Jesús Maestre, Silvia|||0000-0002-1874-4628
  • Cosgaya, Marina
  • García Caldentey, J.
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • López Manzanares, L.
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Ávila Rivera, Maria A.
  • Gómez Mayordomo, V.
  • Nogueira, V.
  • Dotor García-Soto, J.
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Mendoza, Z.
  • Pareés, I.
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, M.G.
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Gastón, I.
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Seijo, Manuel
  • Valero Mayor, Cristina|||0000-0003-3397-2888
  • Alonso Redondo, R.
  • Menéndez González, Manuel
  • McAfee, D.
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Mir, Pablo|||0000-0003-1656-302X
  • Villanueva, Càndid|||0000-0002-3674-914X
  • Vargas, L.
  • Tartari, J. P.
  • Suárez Castro, E.
  • Sierra Peña, María
  • Segundo Rodríguez, J.C.
  • Santacruz, Pilar
  • Sánchez Rodríguez, A.
  • Sánchez Díez, Gemma
  • Sánchez-Carpintero, Macarena
  • Ruíz Martínez, J.
  • Ruíz De Arcos, M.
  • Roldán, F.
  • Rodríguez Pérez, A.B.
  • Rodríguez Méndez, L.
  • Redondo Rafales, N.
  • Puig Daví, A.
  • Pueyo Morlans, Mercedes
  • Puente, V.
  • Prieto Jurczynska, C.
  • Prats, M.A.
  • Planellas, L.
  • Planas-Ballvé, Anna|||0000-0002-8137-0622
  • Pérez Noguera, R.
  • Pérez Fuertes, A.
  • Pastor, P.
  • Pascual Sedano, Berta María|||0000-0002-9298-8241
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Novo Ponte, S.
  • Novo Amado, A.
  • Muro García, I.
  • Moreno Diéguez, A.
  • Morales Casado, M.I.
  • Miranda Santiago, J.
  • Méndez del Barrio, C.
  • Mendoza Plasencia, Z.
  • Meitín, M.T.
  • Martínez Castrillo, J.C.
  • Martí, M.J.
  • Martí Andres, G.
  • Mata, M.
  • Macías, Y.
  • del Lucas Pozo, S.
  • López Seoane, B.
  • López Domínguez, D.
  • López Díaz, L.M.
  • Lastres Gómez, S.
  • Lage Castro, Melva
  • Lacruz, F.
  • Labrador, M.A.
  • Labandeira, C.
  • Kurtis, M.
  • Infante, J.
  • Idoate Calderón, D.
  • Horta-Barba, Andrea|||0000-0003-0050-5466
  • Guardia, G.
  • Grau Solá, M.
  • Golpe Díaz, A.
  • González Toledo, G.R.
  • González Palmás, M.J.
  • González García, B.
  • González Ardura, J.
  • González Aloy, J.
  • Gómez Garre, M.P.
  • García Moreno, J.M.
  • García Díez, C.
  • García Campos, Cristina|||0000-0003-3277-2374
  • Gallego, Miguel|||0000-0002-8882-4033
  • Gámez, P.
  • Fernández Guillán, N.
  • Estelrich Peyret, E.
  • Erro, E.
  • Díez-Fairen, M.
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • Crespo Cuevas, Ane Miren|||0000-0003-1400-5809
  • Cots-Foraster, Anna|||0000-0002-9169-7653
  • Cortina Fernández, Ana
  • Clavero, P.
  • Catalán, M.J.
  • Casas Díaz, Encarna|||0000-0002-5901-6555
  • Carrillo Padilla, Francisco
  • Carrillo, F.
  • Carabajal Pendón, E.
  • Canfield Medina, H.
  • Cabo López, I.
  • Cabello González, Carolina
  • Buongiorno, M.T.
  • Botí, M.|||0000-0003-2963-6929
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Bejr-kasem, Helena|||0000-0001-8828-5976
  • Bernardo Lambrich, N.
  • Ávila, M.A.
  • Aguilar, Mireia
  • Ascunce Vidondo, Arancha
  • Arribas, Sonia
  • Arnáiz, S.
  • Aneiros Díaz, A.
  • Álvarez, I.
  • Alonso Frech, F.
  • Alonso-Cánovas, Araceli|||0000-0003-1702-2655
  • Almeria, Marta|||0000-0001-7445-6113
  • Adarmes, A.D.
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • Vives, B.
  • Cámara Lorenzo, A
Background and objective: Dysphagia at time of diagnosis suggests atypical parkinsonism instead Parkinson's disease (PD). Our aim was to analyze the frequency of dysphagia in patients with early PD comparing with a control group and to identify related factors. Patients and methods: Patients with early PD (≤ 2 years from symptoms onset) who were recruited from January/2016 to November/2017 (baseline visit; V0) and evaluated annually for 5 years from the Spanish cohort COPPADIS were included in this prospective study. Controls were assessed at baseline and at 2-, 4-, and 5-year follow-up. Dysphagia was defined as a score ≥ 1 in the item 20 of the Non-Motor Symptoms Scale (NMSS). Results: Dysphagia was more frequent at baseline in PD patients (19.6% [36/184]; 62.3 ± 8.3 years old; 56.8% males) than in controls (5.3% [11/206]; 60.9 ± 8.3 years old; 50% males) (p < 0.0001) and in all visits as well (p < 0.0001). A worse quality of sleep (Parkinson's Disease Sleep Scale; OR = 0.974; p = 0.005), a greater impulse-control behavior (ICB) (Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale; OR = 1.066; p = 0.014), and non-motor symptoms burden (Non-Motor Symptoms Scale; OR = 1.016; p = 0.021) were independent factors associated with dysphagia at baseline. In those subjects with dysphagia, no differences were observed between patients and controls in the mean NMSS-item 20 overtime, and it didn't change throughout the follow-up. Conclusion: Dysphagia was frequent in early PD patients compared to controls. However, it was minor and did not progress over time. Sleep, ICB, and non-motor symptoms burden were related to dysphagia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Parkinson's disease-subjective cognitive decline and health-related quality of life

  • Rodríguez Antigüedad, Jon|||0000-0002-9316-1772
  • Puig-Davi, Arnau|||0000-0001-8883-4947
  • Franch-Marti, Carla|||0009-0006-2590-4307
  • Bojtos, Lidia
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Alonso Losada, María G.
  • Alonso Redondo, Ruben
  • Álvarez Sauco, María
  • Ávila, Asunción|||0000-0001-8357-0751
  • Borrué, Carmen
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • Caballol, Nuria|||0000-0003-3363-3077
  • Cubo, Esther|||0000-0003-0018-1182
  • Dotor García-Soto, Julio
  • Escalante, Sonia|||0000-0001-8931-1400
  • García Caldentey, Juan
  • García-Ramos, Rocío|||0000-0003-0386-8940
  • Gastón, Itziar
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Infante, Jon|||0000-0003-4025-4606
  • Kurtis, Mónica|||0000-0003-3037-9712
  • Vives, Bárbara
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • López Manzanares, Lydia|||0000-0003-4615-4542
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Mendez-Gonzalez, Manuel|||0000-0002-5218-0774
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Seijo, Manuel
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Valero Merino, Caridad
  • Vela, Lydia|||0000-0001-6663-395X
  • Mir, Pablo|||0000-0003-1656-302X
  • Santos García, Diego|||0000-0002-3126-5111
  • Valero Mayor, Cristina|||0000-0003-3397-2888
  • Santacruz, Pilar
  • Roldán, F.
  • Prats, M. A.
  • Planas-Ballvé, Anna|||0000-0002-8137-0622
  • Pascual-Sedano, B.
  • Pareés, I.
  • Mata, M.
  • Macías, Y.
  • Lacruz, F.
  • Labandeira, C.
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Jesús Maestre, Silvia|||0000-0002-1874-4628
  • Gallego, Miguel|||0000-0002-8882-4033
  • Gámez, P.
  • Fernández, A.
  • de Deus Fonticoba, Teresa
  • Clavero, P.
  • Casas Díaz, Encarna|||0000-0002-5901-6555
  • Carrillo, F.
  • Adarmes-Gómez, A.D.|||0000-0002-1337-9289
  • Martínez-Horta, Saül
  • González-Ortega, Guillermo
  • Pons Pons, Gracia
  • Puy Núñez, Alfredo
  • Ruíz Martínez, J.
  • Pastor, B.V.
  • Valero García, M. F.
  • Torres Moral, A.
  • Tabar Comellas, G.
  • Suárez Fuentes, N.
  • Solleiro Vidal, A.
  • Solares, C.
  • Peña, M.S.
  • Sánchez Pelaez, M. V.
  • Sánchez Martín, M. E.
  • Díez, G.S.
  • San Eufrasio Martínez, M.
  • Roson, M.
  • Rodríguez Pérez, A. B.
  • Rivera Sánchez, M.
  • Ribacoba, C.
  • Rafales, N.R.
  • Noguera, R.P.
  • Pérez Calvo, C.
  • Peral Quirós, A.
  • Ojeda Lepe, E.
  • Ponte, S.N.
  • García, I.M.
  • Muñoz Delgado, L.
  • Morales Casado, M. I.
  • Santiago, J.M.
  • Mandrá, M. A.
  • Macías García, D.
  • Luque Ambrosiani, A. C.
  • del Pozo, S.L.
  • López Valdés, E.
  • Domínguez, D.L.
  • Legarda Ramírez, I.
  • Guardia Valls, G.
  • Solá, M.G.
  • Díaz, A.G.
  • González Palmás, M. J.
  • García, B.G.
  • González Aramburu, I.
  • Aloy, J.G.
  • Gómez Garre, P.
  • Franco Rosado, P.
  • Peyret, E.E.
  • Díaz Galván, P.
  • Foraster, A.C.
  • Castejón Carbó, J.
  • Castellano Guerrero, A. M.
  • Pendón, E.C.
  • González, C.C.
  • Vidondo, A.A.
  • Cánovas, A.A.
  • Almeria Vivó, M.
  • Almarcha Menargues, M.
  • Aldaz, A.
Background: Parkinson's disease-subjective cognitive decline (PD-SCD) is defined by subjective cognitive complaints (SCC) in the absence of objective cognitive impairment and has been associated with an increased risk of future cognitive decline. However, its impact on health-related quality of life (HRQoL) remains unclear. This is particularly relevant in early PD, when patients often maintain high levels of social-occupational functioning and subtle cognitive concerns may interfere with daily life. This study aimed to explore the association between SCC and HRQoL in cognitively unimpaired PD patients (PD-SCD). Methods: Cross-sectional data from the COPPADIS cohort were analyzed. Patients with normal cognition according to PD-MCI level I criteria (Parkinson's Disease-Cognitive Rating Scale > 81) were included. HRQoL was assessed using the 39-item Parkinson's Disease Questionnaire (PDQ-39). SCC were defined as a Non-Motor Symptoms Scale (NMSS) domain 5 ≥ 1. Results: A total of 497 patients with median age 62 years, disease duration 4 years, and 61% of PD-SCD were included. HRQoL was significantly worse in PD-SCD patients across all PDQ-39 domains. In adjusted linear regression models, PD-SCD was independently associated with higher PDQ-39 total score as well as with worse scores in activities of daily living, social support, cognition, and communication domains. Conclusions: PD-SCD is independently associated with poorer HRQoL across multiple domains. These findings highlight the clinical relevance of SCC within a patient-centered approach to PD management.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cognitive impairment and dementia in young onset Parkinson’s disease

  • Santos-García, Diego
  • Deus Fonticoba, T. de
  • Cores Bartolomé, Carlos
  • Feal Painceiras, María J.
  • García Díaz, Iago
  • Íñiguez-Alvarado, María Cristina
  • Paz, José Manuel
  • Jesús Maestre, Silvia
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria
  • Legarda, Inés
  • Hernández-Vara, Jorge
  • Cabo, Iria
  • López-Manzanares, Lydia
  • González-Aramburu, Isabel
  • Ávila-Rivera, María A.
  • Gómez Mayordomo, Víctor
  • Nogueira, Víctor
  • Dotor, Julio
  • Borrué, Carmen
  • Solano Vila, Berta
  • Álvarez-Sauco, María
  • Vela-Desojo, Lydia
  • Escalante, Sonia
  • Cubo, Esther
  • Mendoza, Zebenzui
  • Martinez-Castrillo, Juan Carlos
  • Sánchez Alonso, Pilar
  • Alonso Losada, María G.
  • López-Ariztegui, Nuria
  • Gastón, Itziar
  • Kulisevsky, Jaime
  • Seijo, Manuel
  • Valero, Caridad
  • Alonso Redondo, Rubén
  • Buongiorno, Maria Teresa
  • Ordás, Carlos
  • Menéndez-González, Manuel
  • McAfee, Darrian
  • Martínez-Martín, Pablo
  • Mir, Pablo
  • COPPADIS Study Group
[Background and objective] Patients with young-onset Parkinson’s disease (YOPD) have a slower progression. Our aim was to analyze the change in cognitive function in YOPD compared to patients with a later onset and controls., [Patients and methods] Patients with Parkinson’s disease (PD) and controls from the COPPADIS cohort were included. Cognitive function was assessed with the Parkinson’s Disease Cognitive Rating Scale (PD-CRS) at baseline (V0), 2-year ± 1 month (V2y), and 4-year ± 3 months follow-up (V4y). Regarding age from symptoms onset, patients were classified as YOPD (< 50 years) or non-YOPD (≥ 50). A score in the PD-CRS < 81 was defined as cognitive impairment (CI): ≤ 64 dementia; 65–80 mild cognitive impairment (MCI)., [Results] One-hundred and twenty-four YOPD (50.7 ± 7.9 years; 66.1% males), 234 non-YOPD (67.8 ± 7.8 years; 59.3% males) patients, and 205 controls (61 ± 8.3 years; 49.5% males) were included. The score on the PD-CRS and its subscore domains was higher at all visits in YOPD compared to non-YOPD patients and to controls (p < 0.0001 in all analysis), but no differences were detected between YOPD patients and controls. Only non-YOPD patients had significant impairment in their cognitive function from V0 to V4y (p < 0.0001). At V4y, the frequency of dementia and MCI was 5% and 10% in YOPD compared to 25.2% and 22.3% in non-YOPD patients (p < 0.0001). A lower score on the Parkinson’s Disease Sleep Scale at baseline was a predictor of CI at V4y in YOPD patients (Adjusted R2 = 0.61; OR = 0.965; p = 0.029)., [Conclusion] Cognitive dysfunction progressed more slowly in YOPD than in non-YOPD patients., COPPADIS and the present study were developed with the help of Fundación Española de Ayuda a la Investigación en Enfermedades Neurodegenerativas y/o de Origen Genético (https://fundaciondegen.org/) and Alpha Bioresearch (www.alphabioresearch.com). Also, we received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017–2020 por el Proyecto “PROGRESIÓN NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”) to develop a part of the COPPADIS project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Corticospinal adaptations following resistance training and its relationship with strength: A systematic review and multivariate meta-analysis

  • Gómez-Feria, José
  • Martín-Rodríguez, Juan Francisco
  • Mir, Pablo
© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/)., Neural adaptations to resistance training (RT) and their correlation with muscle strength remain partially understood. We conducted a systematic review and multivariate meta-analysis to examine the effects of metronome-paced (MP), self-paced (SP), and isometric (IM) training on M1 and corticospinal pathway activity. Following MP RT, a significant increase in corticospinal excitability was observed, correlating with increased strength. Conversely, no significant relationship was found after SP or IM training. RT also reduced the duration of the cortical silent period, but this change did not predict strength changes and was not specific to any training modality. No significant effects were found for short-interval intracortical inhibition. Our findings suggest that changes in corticospinal excitability may contribute to strength gains after RT. Furthermore, the relationship between these adaptations and strength appears dependent on the type of training performed., This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, PI22/01704], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía [PY20_00896], and the Fundación Alicia Koplowitz. JG-F is supported by the Ministerio de Ciencia e Innovación (Grant FPU16/03550). JFM-R is supported by VI-PPIT-US from the University of Seville (USE-18817-A)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Homocysteine levels, genetic background, and cognitive impairment in Parkinson’s disease

  • Periñán, María Teresa
  • Macías García, Daniel
  • Jesús Maestre, Silvia
  • Martín-Rodríguez, Juan Francisco
  • Muñoz-Delgado, Laura
  • Jiménez-Jaraba, María Valle
  • Buiza-Rueda, Dolores
  • Bonilla-Toribio, Marta
  • Adarmes-Gómez, Astrid
  • Gómez-Garre, Pilar
  • Mir, Pablo
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/., [Background] Hyperhomocysteinemia is considered an independent risk factor for cognitive impairment., [Objective] To study the correlation between homocysteine levels and cognitive impairment in patients with PD., [Methods] We conducted a case–control study that included 246 patients with PD, of whom 32 were cognitively impaired. The levels of homocysteine, folate, and vitamin B12 were measured in peripheral blood. Multivariate logistic regression analysis was applied to determine differences in homocysteine levels between PD patients with and without cognitive impairment. A meta-analysis was performed to clarify the role of Hcy levels in PD with cognitive decline. Five polymorphisms in genes involved in Hcy metabolism, including MTHFR rs1801133 and rs1801131, COMT rs4680, MTRR rs1801394, and TCN2 rs1801198, were genotyped., [Results] Our case–control study showed that homocysteine levels were associated with cognitive impairment in PD after adjusting for possible confounding factors such as levodopa equivalent daily dose. The results of our meta-analysis further supported the positive association between homocysteine levels and cognition in PD. We found that the MTHFR rs1801133 TT genotype led to higher homocysteine levels in PD patients, whereas the MTHFR rs1801131 CC genotype resulted in higher folate levels. However, the polymorphisms studied were not associated with cognitive impairment in PD., [Conclusions] Increased homocysteine levels were a risk factor for cognitive decline in PD. However, no association was found between polymorphisms in genes involved in homocysteine metabolism and cognitive impairment in PD. Large-scale studies of ethnically diverse populations are required to definitively assess the relationship between MTHFR and cognitive impairment in PD., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], and the Fundación Alicia Koplowitz. Pilar Gómez-Garre was supported by the “Nicolás Monardes” program [C-0048-2017] (from Andalusian Regional Ministry of Health). Silvia Jesús was supported by the "Acción B Clínicos Investigadores” program from the Consejería de Salud y Familias de la Junta de Andalucía [B-0007-2019]. Daniel Macías-García was supported by the “Río Hortega” program [CM18/00142] from the Instituto de Salud Carlos III (ISCIII-FEDER). Juan Francisco Martín-Rodríguez was supported by the VI-PPIT-US from the University of Seville [USE-18817-A]. Laura Muñoz-Delgado was supported by the “Río Hortega” program [CM21/00051] from the Instituto de Salud Carlos III (ISCIII-FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

How can I assess my patients with Parkinson's disease during a busy clinic day?

  • Cubo, Esther
  • García-Bustillo, Álvaro
  • Calvo, Sara
  • Gámez-Leyva, Gonzalo
  • Simón-Vicente, Lucia
  • Rivadeneyra, Jessica
  • Miranda, Javier
  • Madrigal, Elisabet
  • Martínez-Martín, Pablo
  • Mir, Pablo
  • Santos-García, Diego
  • COPPADIS Study Group
[Background] The evaluation of motor impairment in Parkinson's disease (PD) is mainly assessed with the motor subdomain of the Unified Parkinson's Disease Rating scale (UPDRS part III) and, lately, with the MDS-UPDRS part III. To optimize efforts and special needs during specific circumstances in clinical practice, we sought to identify the most sensitive items to assess motor impairment in PD., [Methods] We included the COPPADIS-PD cohort and collected the UPDRS part III at baseline (V0), 12 months (V1), and 24 months (V2). Factor analysis and effect size using Cohen's d formula were performed in the Off and On states at V0, V1, and V2., [Results] We included 667 patients with PD, mean age of 62.59 ± 8.91 years, 410 (60.2%) males, with a median HY stage of 2.00 (1.00; 4.00) at baseline. Over time, the most discriminating items were postural stability and body bradykinesia (“arise from chair” and “gait”) in the Off state, right and left upper extremity bradykinesia ("finger tap", "hand movements" and "prono/supination") in the On state. Body bradykinesia and right-left finger tapping were the items with the largest effect size (0.93, 0.84, 0.83, respectively) to assess motor improvement after receiving antiparkinsonian medications over time., [Conclusion] Under specific circumstances, selecting a few items of the UPDRS part III, including postural stability, body bradykinesia, and upper extremity bradykinesia, could be used to create a quick clinical judgment of motor status and improvement in PD., This work was supported by the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI20/00613], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Fundación Alicia Koplowitz and the Fundación "Curemos el Parkinson"., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease

  • Muñoz-Delgado, Laura
  • Labrador, Miguel Ángel
  • Macías García, Daniel
  • Jesús Maestre, Silvia
  • Benítez Zamora, Belén
  • Fernández-Rodríguez, Paula
  • Adarmes-Gómez, Astrid
  • Reina-Castillo, María Isabel
  • Castro-Labrador, Sandra
  • Silva-Rodríguez, Jesús
  • Carrillo, Fátima
  • García-Solís, David
  • Grothe, Michel J.
  • Mir, Pablo
© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., [Background] Peripheral inflammatory immune responses are suggested to play a major role in dopaminergic degeneration in Parkinson's disease (PD). The neutrophil-to-lymphocyte ratio (NLR) is a well-established biomarker of systemic inflammation in PD. Degeneration of the nigrostriatal dopaminergic system can be assessed in vivo using [123I]FP-CIT single photon emission computed tomography imaging of striatal dopamine transporter (DAT) density., [Objectives] To assess the relationship between the peripheral immune profile (NLR, lymphocytes, and neutrophils) and striatal DAT density in patients with PD., [Methods] We assessed clinical features, the peripheral immune profile, and striatal [123I]FP-CIT DAT binding levels of 211 patients with PD (primary-cohort). Covariate-controlled associations between the immune response and striatal DAT levels were assessed using linear regression analyses. For replication purposes, we also studied a separate cohort of 344 de novo patients with PD enrolled in the Parkinson's Progression Markers Initiative (PPMI-cohort)., [Results] A higher NLR was significantly associated with lower DAT levels in the caudate (primary-cohort: β = −0.01, p < 0.001; PPMI-cohort: β = −0.05, p = 0.05) and the putamen (primary-cohort: β = −0.05, p = 0.02; PPMI-cohort: β = −0.06, p = 0.02). Intriguingly, a lower lymphocyte count was significantly associated with lower DAT levels in both the caudate (primary-cohort: β = +0.09, p < 0.05; PPMI-cohort: β = +0.11, p = 0.02) and the putamen (primary-cohort: β = +0.09, p < 0.05, PPMI-cohort: β = +0.14, p = 0.01), but an association with the neutrophil count was not consistently observed (caudate; primary-cohort: β = −0.05, p = 0.02; PPMI-cohort: β = 0, p = 0.94; putamen; primary-cohort: β = −0.04, p = 0.08; PPMI-cohort: β = −0.01, p = 0.73)., [Conclusions] Our findings across two independent cohorts suggest a relationship between systemic inflammation and dopaminergic degeneration in patients with PD. This relationship was mainly driven by the lymphocyte count. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society., Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía. Grant Numbers: CTS-7685, CVI-02526, Consejería de Salud y Bienestar Social de la Junta de Andalucía. Grant Numbers: PE-0186-2019, PE-0210-2018, PI-0459-2018, PI-0471-2013, Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía. Grant Number: PY20_00896, Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER). Grant Numbers: PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease

  • Muñoz-Delgado, Laura
  • Macías García, Daniel
  • Periñán, María Teresa
  • Jesús Maestre, Silvia
  • Adarmes-Gómez, Astrid
  • Bonilla-Toribio, Marta
  • Buiza-Rueda, Dolores
  • Jiménez-Jaraba, María Valle
  • Benítez Zamora, Belén
  • Díaz-Belloso, Rafael
  • García-Díaz, Sergio
  • Martín Bórnez, Miguel
  • Pineda-Sánchez, Rocío
  • Carrillo, Fátima
  • Gómez-Garre, Pilar
  • Mir, Pablo
© The Author(s) 2023, corrected publication 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/., Peripheral inflammatory immune responses are thought to play a major role in the pathogenesis of Parkinson’s disease (PD). The neutrophil-to-lymphocyte ratio (NLR), a biomarker of systemic inflammation, has been reported to be higher in patients with PD than in healthy controls (HCs). The present study was aimed at determining if the peripheral inflammatory immune response could be influenced by the genetic background of patients with PD. We included a discovery cohort with 222 patients with PD (132 sporadic PD, 44 LRRK2-associated PD (with p.G2019S and p.R1441G variants), and 46 GBA-associated PD), as well as 299 HCs. Demographic and clinical data were recorded. Leukocytes and their subpopulations, and the NLR were measured in peripheral blood. Multivariate lineal regression and post-hoc tests were applied to determine the differences among the groups. Subsequently, a replication study using the Parkinson’s Progression Markers Initiative cohort was performed which included 401 patients with PD (281 sPD patients, 66 LRRK2-PD patients, 54 GBA-PD patients) and a group of 174 HCs. Patients with sporadic PD and GBA-associated PD showed a significantly lower lymphocyte count, a non-significantly higher neutrophil count and a significantly higher NLR than HCs. The peripheral inflammatory immune response of patients with LRRK2-associated PD did not differ from HCs. Our study supports the involvement of a peripheral inflammatory immune response in the pathophysiology of sPD and GBA-associated PD. However, this inflammatory response was not found in LRRK2-associated PD, probably reflecting different pathogenic inflammatory mechanisms., The authors thank the donors and the Hospital Universitario Virgen del Rocío-Instituto de Biomedicina de Sevilla Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT17/0015/0041) for the human specimens used in this study. This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, and PI22/01704], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía [PY20_00896], and the Fundación Alicia Koplowitz. Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases – Project ID No 739510. Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048-2017; from the Andalusian Regional Ministry of Health). Silvia Jesús was supported by the “Acción B Clínicos Investigadores” program from the Consejería de Salud y Familias, Junta de Andalucía (B-0007-2019). Daniel Macías-Garcia was supported by the “Juan Rodés” program (JR22/00073) from the Instituto de Salud Carlos III. Laura Muñoz-Delgado was supported by the “Río Hortega” program (CM21/00051) from the Instituto de Salud Carlos III. Rafael Díaz Belloso was supported by pre-doctoral contract for training in health research (PFIS) from Instituto de Salud Carlos III. Sergio García Díaz was supported by an University Teacher Training Programme (FPU) from the Spanish Ministry of Education., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Prevalence and Factors Associated with Drooling in Parkinson’s Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group

  • Santos-García, Diego
  • Deus Fonticoba, T. de
  • Cores Bartolomé, Carlos
  • Feal Painceiras, María J.
  • Íñiguez-Alvarado, María Cristina
  • Jesús Maestre, Silvia
  • Buongiorno, Maria Teresa
  • Planellas, Lluís
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria
  • Legarda, Inés
  • Hernández-Vara, Jorge
  • Cabo, Iria
  • López-Manzanares, Lydia
  • González-Aramburu, Isabel
  • Ávila-Rivera, María A.
  • Gómez Mayordomo, Víctor
  • Nogueira, Víctor
  • Puente, Víctor
  • Dotor, Julio
  • Borrué, Carmen
  • Solano Vila, Berta
  • Álvarez-Sauco, María
  • Vela-Desojo, Lydia
  • Escalante, Sonia
  • Cubo, Esther
  • Carrillo Padilla, Francisco
  • Martinez-Castrillo, Juan Carlos
  • Sánchez Alonso, Pilar
  • Alonso Losada, María G.
  • López-Ariztegui, Nuria
  • Gastón, Itziar
  • Kulisevsky, Jaime
  • Blázquez-Estrada, Marta
  • Seijo, Manuel
  • Ruiz Martínez, Javier
  • Valero, Caridad
  • Kurtis, Mónica
  • Fábregues-Boixar, Oriol de
  • González Ardura, Jessica
  • Alonso Redondo, Rubén
  • Ordás, Carlos
  • López-Díaz, Luis M.
  • McAfee, Darrian
  • Martínez-Martín, Pablo
  • Mir, Pablo
  • Study Group COPPADIS
© 2023 Diego Santos-García et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited., Introduction. Drooling in Parkinson’s disease (PD) is frequent but often goes underrecognized. Our aim was to examine the prevalence of drooling in a PD cohort and compare it with a control group. Specifcally, we identifed factors associated with drooling and conducted subanalyses in a subgroup of very early PD patients. Patients and Methods. PD patients who were recruited from January 2016 to November 2017 (baseline visit; V0) and evaluated again at a 2-year ± 30-day follow-up (V2) from 35 centers in Spain from the COPPADIS cohort were included in this longitudinal prospective study. Subjects were classifed as with or without drooling according to item 19 of the NMSS (Nonmotor Symptoms Scale) at V0, V1 (1-year ± 15 days), and V2 for patients and at V0 and V2 for controls. Results. Te frequency of drooling in PD patients was 40.1% (277/691) at V0 (2.4% (5/201) in controls; p < 0.0001), 43.7% (264/604) at V1, and 48.2% (242/502) at V2 (3.2% (4/124) in controls; p < 0.0001), with a period prevalence of 63.6% (306/481). Being older (OR = 1.032; p = 0.012), being male (OR = 2.333; p < 0.0001), having greater nonmotor symptom (NMS) burden at the baseline (NMSS total score at V0; OR = 1.020; p < 0.0001), and having a greater increase in the NMS burden from V0 to V2 (change in the NMSS total score from V0 to V2; OR = 1.012; p < 0.0001) were identifed as independent predictors of drooling after the 2-year follow-up. Similar results were observed in the group of patients with ≤2 years since symptom onset, with a cumulative prevalence of 64.6% and a higher score on the UPDRS-III at V0 (OR = 1.121; p = 0.007) as a predictor of drooling at V2. Conclusion. Drooling is frequent in PD patients even at the initial onset of the disease and is associated with a greater motor severity and NMS burden., COPPADIS and the present study were developed with the help of Fundación Española de Ayuda a la Investigación en Enfermedades Neurodegenerativas y/o de Origen Genético (https://fundaciondegen.org/) and Alpha Bioresearch (https://www.alphabioresearch.com). Also, The authors received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017–2020 por el proyecto “PROGRESIÓN NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”) to develop a part of the COPPADIS project. The authors would like to thank all patients and their caregivers who collaborated in this study. They would also like to thank Fundación Española de Ayuda a la Investigación en Enfermedades Neurodegenerativas y/o de Origen Genético (https://fundaciondegen.org/) and Alpha Bioresearch (https://www.alphabioresearch.com) and other institutions for helping them., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Response to levodopa in Parkinson's disease over time. A 4-year follow-up study

  • Santos-García, Diego
  • Deus Fonticoba, T. de
  • Cores Bartolomé, Carlos
  • Feal Painceiras, María J.
  • García Díaz, Iago
  • Íñiguez-Alvarado, María Cristina
  • Paz, José Manuel
  • Jesús Maestre, Silvia
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria
  • Legarda, Inés
  • González-Aramburu, Isabel
  • Ávila-Rivera, María A.
  • Gómez Mayordomo, Víctor
  • Vela-Desojo, Lydia
  • Escalante, Sonia
  • Mendoza, Zebenzui
  • Martinez-Castrillo, Juan Carlos
  • Sánchez Alonso, Pilar
  • Alonso Losada, María G.
  • López-Ariztegui, Nuria
  • McAfee, Darrian
  • Martínez-Martín, Pablo
  • Mir, Pablo
  • COPPADIS Study Group
[Background and objective] A good response to levodopa is a key factor to indicate device-aided therapies in people with Parkinson's disease (PwPD). The aim of the present study was to analyze the response to levodopa in PwPD with motor fluctuations followed for 4 years., [Patients and methods] PwPD with motor fluctuations recruited from January 2016 to November 2017 from the COPPADIS cohort and assessed annually (from baseline to 4-year follow-up) during the OFF and ON states were included in this analysis. At each visit, the Unified Parkinson's Disease Rating Scale – part III (UPDRS-III) was applied during the OFF state (without medication during the last 12 h) and during the ON state. General linear model repeated measures were used to test for changes in the mean UPDRS–III–OFF, UPDRS–III–ON, and ΔUPDRS-III (UPDRS–III–OFF – UPDRS–III–ON) between visits. Levodopa equivalent daily dose (LEDD) was included as covariate., [Results] Sixty-three patients (63.94 ± 8.42 years old; 68.3% males) were included. Mean disease duration was 7.81 ± 3.64 years. From baseline to 4-year follow-up visit, a significant increase in both the UPDRS–III–OFF (from 27.98 ± 9.58 to 31.75 ± 12.39; p = 0.003) and the UPDRS–III–ON (from 15.92 ± 7.93 to 18.84 ± 8.17; p = 0.006) was observed despite the significant increase in the LEDD (from 896.35 ± 355.65 to 1085.51 ± 488.29; p = 0.003). However, no significant differences were detected between visits in the ΔUPDRS-III., [Conclusion] In this cohort of PwPD with motor fluctuations, the response to levodopa did not weaken after a 4-year follow-up., COPPADIS and the present study were developed with the help of Fundación Española de Ayuda a la Investigación en Enfermedades Neurodegenerativas y/o de Origen Genético (https://fundaciondegen.org/) and Alpha Bioresearch (www.alphabioresearch.com). Also, we received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017–2020 por el Proyecto “PROGRESIÓN NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”) to develop a part of the COPPADIS project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Risk of Cognitive Impairment in Patients With Parkinson’s Disease With Visual Hallucinations and Subjective Cognitive Complaints

  • Santos-García, Diego
  • Deus Fonticoba, T. de
  • Cores Bartolomé, Carlos
  • Feal Painceiras, María J.
  • Paz González, J. M.
  • Martínez Miró, Cristina
  • Jesús Maestre, Silvia
  • Aguilar, Miquel
  • Pastor, Pau
  • Planellas, Lluís
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria
  • Legarda, Inés
  • Hernández-Vara, Jorge
  • Cabo, Iria
  • López-Manzanares, Lydia
  • González-Aramburu, Isabel
  • Maria A. Ávila Rivera,o
  • Gómez Mayordomo, Víctor
  • Nogueira, Víctor
  • Puente, Víctor
  • Dotor, Julio
  • Borrué, Carmen
  • Solano Vila, Berta
  • Álvarez-Sauco, María
  • Vela-Desojo, Lydia
  • Escalante, Sonia
  • Cubo, Esther
  • Carrillo Padilla, Francisco
  • Martinez-Castrillo, Juan Carlos
  • Sánchez Alonso, Pilar
  • Alonso Losada, María G.
  • López-Ariztegui, Nuria
  • Gastón, Itziar
  • Kulisevsky, Jaime
  • Blázquez-Estrada, Marta
  • Seijo, Manuel
  • Ruiz Martínez, Javier
  • Valero, Caridad
  • Kurtis, Mónica
  • Fábregues-Boixar, Oriol de
  • González Ardura, Jessica
  • Alonso Redondo, Rubén
  • Ordás, Carlos
  • López-Díaz, Luis M.
  • McAfee, Darrian
  • Martínez-Martín, Pablo
  • Mir, Pablo
  • COPPADIS Study Group
© 2023 Korean Neurological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited., [Background and Purpose] Visual hallucinations (VH) and subjective cognitive complaints (SCC) are associated with cognitive impairment (CI) in Parkinson’s disease. Our aims were to determine the association between VH and SCC and the risk of CI development in a cohort of patients with Parkinson’s disease and normal cognition (PD-NC)., [Methods] Patients with PD-NC (total score of >80 on the Parkinson’s Disease Cognitive Rating Scale [PD-CRS]) recruited from the Spanish COPPADIS cohort from January 2016 to November 2017 were followed up after 2 years. Subjects with a score of ≥1 on domain 5 and item 13 of the Non-Motor Symptoms Scale at baseline (V0) were considered as “with SCC” and “with VH,” respectively. CI at the 2-year follow-up (plus or minus 1 month) (V2) was defined as a PD-CRS total score of <81., [Results] At V0 (n=376, 58.2% males, age 61.14±8.73 years [mean±SD]), the frequencies of VH and SCC were 13.6% and 62.2%, respectively. VH were more frequent in patients with SCC than in those without: 18.8% (44/234) vs 4.9% (7/142), p<0.0001. At V2, 15.2% (57/376) of the patients had developed CI. VH presenting at V0 was associated with a higher risk of CI at V2 (odds ratio [OR]=2.68, 95% confidence interval=1.05–6.83, p=0.0.039) after controlling for the effects of age, disease duration, education, medication, motor and nonmotor status, mood, and PD-CRS total score at V0. Although SCC were not associated with CI at V2, presenting both VH and SCC at V0 increased the probability of having CI at V2 (OR=3.71, 95% confidence interval=1.36–10.17, p=0.011)., [Conclusions] VH were associated with the development of SCC and CI at the 2-year follow-up in patients with PD-NC., The resources obtained for the development of this project have been obtained by the Degen Foundation (https://fundaciondegen.org/). A part of the Project is financed with grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017-2020 por el proyecto “PROGRESIÓN NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Staging Parkinson’s Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life

  • Santos-García, Diego
  • Deus Fonticoba, T. de
  • Cores Bartolomé, Carlos
  • Feal Painceiras, María J.
  • Íñiguez-Alvarado, María Cristina
  • García Díaz, Iago
  • Jesús Maestre, Silvia
  • Buongiorno, Maria Teresa
  • Planellas, Lluís
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria
  • Legarda, Inés
  • Hernández-Vara, Jorge
  • Cabo, Iria
  • López-Manzanares, Lydia
  • González-Aramburu, Isabel
  • Ávila-Rivera, María A.
  • Gómez Mayordomo, Víctor
  • Nogueira, Víctor
  • Puente, Víctor
  • Dotor, Julio
  • Borrué, Carmen
  • Solano Vila, Berta
  • Álvarez-Sauco, María
  • Vela-Desojo, Lydia
  • Escalante, Sonia
  • Cubo, Esther
  • Carrillo Padilla, Francisco
  • Martinez-Castrillo, Juan Carlos
  • Sánchez Alonso, Pilar
  • Alonso Losada, María G.
  • López-Ariztegui, Nuria
  • Gastón, Itziar
  • Kulisevsky, Jaime
  • Menéndez-González, Manuel
  • Seijo, Manuel
  • Ruiz Martínez, Javier
  • Valero, Caridad
  • Kurtis, Mónica
  • González Ardura, Jessica
  • Alonso Redondo, Rubén
  • Ordás, Carlos
  • López-Díaz, Luis M.
  • McAfee, Darrian
  • Calopa, Matilde
  • Carrillo, Fátima
  • Escamilla-Sevilla, Francisco
  • Freire, Eric
  • Gómez Esteban, Juan Carlos
  • García-Ramos, Rocío
  • Luquín, María Rosario Isabel
  • Martínez Torres, Irene
  • Sesar Ignacio, Ángel
  • Martínez-Martín, Pablo
  • Mir, Pablo
  • COPPADIS Study Group
© 2023 – The authors. Published by IOS Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0)., Background: Recently, a novel simple classification called MNCD, based on 4 axes (Motor; Non-motor; Cognition; Dependency) and 5 stages, has been proposed to classify Parkinson's disease (PD)., Objective: Our aim was to apply the MNCD classification in a cohort of PD patients for the first time and also to analyze the correlation with quality of life (QoL) and disease severity., Methods: Data from the baseline visit of PD patients recruited from 35 centers in Spain from the COPPADIS cohort fromJanuary 2016 to November 2017 were used to apply the MNCD classification. Three instruments were used to assess QoL:1) the 39-item Parkinson's disease Questionnaire [PDQ-39]); PQ-10; the EUROHIS-QOL 8-item index (EUROHIS-QOL8)., Results: Four hundred and thirty-nine PD patients (62.05±7.84 years old; 59% males) were included. MNCD stage was:stage 1, 8.4% (N = 37); stage 2, 62% (N = 272); stage 3, 28.2% (N = 124); stage 4-5, 1.4% (N = 6). A more advancedMNCD stage was associated with a higher score on the PDQ39SI (p < 0.0001) and a lower score on the PQ-10 (p< 0.0001) and EUROHIS-QOL8 (p< 0.0001). In many other aspects of the disease, such as disease duration, levodopa equivalent daily dose, motor symptoms, non-motor symptoms, and autonomy for activities of daily living, an association between the stage and severity was observed, with data indicating a progressive worsening related to disease progression throughout the proposed stages., Conclusion: Staging PD according to the MNCD classification correlated with QoL and disease severity. The MNCD could be a proper tool to monitor the progression of PD., COPPADIS and the present study were developed with the help of Fundación Española de Ayuda a la Investigación en Enfermedades Neurodegenerativas y/o de Origen Genético (https://fundaciondegen.org/) and Alpha Bioresearch (www.alphabioresearch.com). Also, we received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017-2020 por el Proyecto “PROGRESION NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”) to develop a part of the COPPADIS project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden

  • Santos-García, Diego
  • Deus Fonticoba, T. de
  • Cores Bartolomé, Carlos
  • Feal Painceiras, María J.
  • García Díaz, Iago
  • Íñiguez-Alvarado, María Cristina
  • Paz, José Manuel
  • Jesús Maestre, Silvia
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria
  • Legarda, Inés
  • Hernández-Vara, Jorge
  • Cabo, Iria
  • López-Manzanares, Lydia
  • González-Aramburu, Isabel
  • Ávila-Rivera, María A.
  • Gómez Mayordomo, Víctor
  • Nogueira, Víctor
  • Dotor, Julio
  • Borrué, Carmen
  • Solano Vila, Berta
  • Álvarez-Sauco, María
  • Vela-Desojo, Lydia
  • Escalante, Sonia
  • Cubo, Esther
  • Mendoza, Zebenzui
  • Martinez-Castrillo, Juan Carlos
  • Sánchez Alonso, Pilar
  • Alonso Losada, María G.
  • López-Ariztegui, Nuria
  • Gastón, Itziar
  • Kulisevsky, Jaime
  • Seijo, Manuel
  • Valero, Caridad
  • Alonso Redondo, Rubén
  • Buongiorno, Maria Teresa
  • Ordás, Carlos
  • Menéndez-González, Manuel
  • McAfee, Darrian
  • Martínez-Martín, Pablo
  • Mir, Pablo
  • COPPADIS Study Group
© 2023 The Authors. Brain and Behavior published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited., [Background and objective] Recently, we demonstrated that staging Parkinson's disease (PD) with a novel simple classification called MNCD, based on four axes (motor, non-motor, cognition, and dependency) and five stages, correlated with disease severity and patients’ quality of life. Here, we analyzed the correlation of MNCD staging with PD caregiver's status., [Patients and methods] Data from the baseline visit of PD patients and their principal caregiver recruited from 35 centers in Spain from the COPPADIS cohort from January 2016 to November 2017 were used to apply the MNCD total score (from 0 to 12) and MNCD stages (from 1 to 5) in this cross-sectional analysis. Caregivers completed the Zarit Caregiver Burden Inventory (ZCBI), Caregiver Strain Index (CSI), Beck Depression Inventory-II (BDI-II), PQ-10, and EUROHIS-QOL 8-item index (EUROHIS-QOL8)., [Results] Two hundred and twenty-four PD patients (63 ± 9.6 years old; 61.2% males) and their caregivers (58.5 ± 12.1 years old; 67.9% females) were included. The frequency of MNCD stages was 1, 7.6%; 2, 58.9%; 3, 31.3%; and 4–5, 2.2%. A more advanced MNCD stage was associated with a higher score on the ZCBI (p < .0001) and CSI (p < .0001), and a lower score on the PQ-10 (p = .001), but no significant differences were observed in the BDI-II (p = .310) and EUROHIS-QOL8 (p = .133). Moderate correlations were observed between the MNCD total score and the ZCBI (r = .496; p < .0001), CSI (r = .433; p < .0001), and BDI-II (r = .306; p < .0001) in caregivers., [Conclusion] Staging PD according to the MNCD classification is correlated with caregivers’ strain and burden., Diego Santos-García has received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017–2020 por el proyecto “PROGRESIÓN NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”). Teresa de Deus Fonticoba: None. Carlos Cores Bartolomé has received honoraria for educational presentations and advice service by Lundbeck and UCB Pharma. María J. Feal Painceiras: None. Iago García Díaz has received support for educational activity from Bial., Silvia Jesús holds the competitive contract “Juan Rodés” supported by the Instituto de Salud Carlos III. She has received grants from the Spanish Ministry of Economy and Competitiveness (PI18/01898) and the Consejería de Salud de la Junta de Andalucía (PI-0459-2018)., Manuel Menéndez-González has received research grants from by Instituto de Salud Carlos III (ISCIII), Fondo Europeo de Desarrollo Regional (FEDER), and Fundación Alimerka., Pablo Mir has received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Subdirección General de Evaluación y Fomento de la Investigación) and by Fondo Europeo de Desarrollo Regional (FEDER), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [ PI-0437-2012, PI-0471-2013], the Sociedad Andaluza de Neurología, the Jacques and Gloria Gossweiler Foundation, the Fundación Alicia Koplowitz, the Fundación Mutua Madrileña., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline

  • Rodríguez-Antigüedad, Jon
  • Martínez-Horta, Saúl
  • Puig-Davi, Arnau
  • Horta-Barba, Andrea
  • Pagonabarraga-Mora, Javier
  • Deus Fonticoba, T. de
  • Jesús Maestre, Silvia
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Ávila-Rivera, María A.
  • Caballol, Nuria
  • Legarda, Inés
  • Hernández-Vara, Jorge
  • Cabo-Lopez, Iria
  • López-Manzanares, Lydia
  • González-Aramburu, Isabel
  • Gómez Mayordomo, Víctor
  • González Ardura, Jessica
  • Dotor García-Soto, Julio
  • Borrué, Carmen
  • Solano Vila, Berta
  • Álvarez-Sauco, María
  • Vela-Desojo, Lydia
  • Escalante, Sonia
  • Cubo, Esther
  • Mendoza, Zebenzui
  • Pareés, Isabel
  • Sánchez Alonso, Pilar
  • Alonso Losada, María G.
  • López-Ariztegui, Nuria
  • Gastón, Itziar
  • Ruíz-Martínez, Javier
  • Buongiorno, Maria Teresa
  • Ordás, Carlos
  • Valero, Caridad
  • Puente, Víctor
  • Kurtis, Mónica
  • Blázquez-Estrada, Marta
  • Martínez-Martín, Pablo
  • Mir, Pablo
  • Santos-García, Diego
  • Kulisevsky, Jaime
[Background] Parkinson’s Disease (PD)-associated subjective cognitive decline (PDSCD) is defined as cognitive complaints without objective cognitive impairment. Based on most studies, it is associated with a greater risk of cognitive decline and may represent a prodromal stage of cognitive impairment., [Methods] The main objectives are to identify cognitive progression patterns and clinical predictors of worse cognitive decline within a large PD-SCD cohort with a 4-year followup. All patients belong to the prospective observational multicenter study COPPADIS., [Results] A total of 198 PD-SCD subjects were analyzed. Mean age was 60.9, mean disease duration 5.2, and mean PD-Cognitive Rating Scale (PD-CRS) 97.6. Subjects were classified as Progressors if their Reliable Change Index was ≤ − 1.64 at year 4, and as non-Progressors if it was > − 1.64 (− 1.64 corresponded to − 16 on the PD-CRS). Progressors had significantly higher age, Movement Disorders Society-Unified PD Rating Scale (MDS-UPDRS) III, levodopa equivalent daily-dose, Non-Motor Symptom Scale total score, memory-related cognitive complaints, and prevalence of REM-sleep behavior disorder (RBD) at baseline. A linear mixed-effects model showed divergent cognitive trajectories between Progressors and non-Progressors (estimate = − 26.8; p < 0.001), with no differences in motor trajectories. In the binary regression model, age (OR = 1.09; p = 0.001), MDS-UPDRS III (OR = 1.05, p = 0.008), and RBD (OR = 2.55, p = 0.010) at baseline were independent predictors of cognitive progression., [Conclusions] Subjects with PD-SCD do not consistently show cognitive decline, but rather exhibit a heterogeneous progression. Age, MDS-UPDRS III and RBD significantly increase the risk of a more aggressive cognitive phenotype. Future research on biomarkers will help explore additional cognitive predictors in PD-SCD., Open Access Funding provided by Universitat Autonoma de Barcelona. COPPADIS and the present study were developed with the help of Fundación Española de Ayuda a la Investigación en Enfermedades Neurodegenerativas y/o de Origen Genético (https://fundaciondegen.org/) and Alpha Bioresearch (www.alphabioresearch.com). We also received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017–2020 por el Proyecto “PROGRESIÓN NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”) to develop a part of the COPPADIS project. JRA: has received honoraria for educational presentations by Zambon. SMH: SMH has received honoraria for lecturing from: Teva, Zambon, UCB, and Roche, and reports grants from Huntington’s disease Society of America (Human Biology Project), and from Fondo de Investigaciones Sanitarias (FIS) from Instituto de Salud Carlos III (ISCIII). APD: none. AHB: none. JP: has served on advisory or speakers' boards, and received honoraria from: UCB, Zambon, AbbVie, Italfarmaco, Allergan, Ipsen, Bial and reports grants from Fundació la Marato de TV3, Fondo de Investigaciones Sanitarias (FIS) and from Instituto de Salud Carlos III (ISCIII). TDF: none. SJ: has received honoraria from AbbVie, Bial, Merz, UCB, and Zambon and holds the competitive contract "Juan Rodés" supported by the Instituto de Salud Carlos III. She has received grants from the Spanish Ministry of Economy and Competitiveness (PI18/01898) and the Consejería de Salud de la Junta de Andalucía (PI-0459–2018). MC: none. JGC: has received honoraria for educational presentations and advice service by Qualigen, Nutricia, Abbvie, Italfarmaco, UCB Pharma, Lundbeck, Zambon, Bial, and Teva. MAAR: has received honoraria from Zambon, UCB Pharma, Qualigen, Bial, and Teva, and sponsorship from Zambon and Teva for attending conferences. NC: has received honoraria from Bial, Italfármaco, Qualigen, Zambon, UCB, Teva and KRKA and sponsorship from Zambon, TEVA and Abbvie for attending medical conferences. IL: has received honoraria for educational presentations and advice service by Qualigen, Nutricia, Abbvie, UCB Pharma, Zambon, Bial, and Teva. JHV: has received travel bursaries and educational grants from Abbvie and has received honoraria for educational presentations from Abbvie, Teva, Bial, Zambon, Italfarmaco, and Sanofi-Genzyme. IC: has received honoraria for educational presentations and advice service by Abbvie, Zambon, and Bial. LLM: compensated advisory services, consulting, research grant support, or speaker honoraria: AbbVie, Acorda, Bial, Intec Pharma, Italfarmaco, Pfizer, Roche, Teva, UCB, and Zambon. IGA: none. VGM: has received honoraria from Bial, Merz and Zambon for educational lectures. JGA: none. JDGS: compensated advisory services, consulting, research grant support, or speaker honoraria: Merck, Sanofi-Genzyme, Allergan, Biogen, Roche, UCB and Novartis. CB: none. BSV: has received honoraria for educational presentations and advice service by UCB, Zambon, Teva, Abbvie, Bial. MAS: has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Zambon, Bial, and Teva. LV: has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, and Teva. SE: has received honoraria for educational presentations and advice service by Abbvie, Zambon, and Bial. EC: Travel grants: Abbvie, Allergan, Boston; Lecturing honoraria: Abbvie, International Parkinson´s disease Movement Disorder Society. ZM: none. IP: has received honoraria from Lundbeck, Krka, TEVA, UCB, Zambon, Allergan, Ipsen, and Merz. PSA: has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, and Teva. MGAL: has received honoraria for educational presentations and advice service by Zambon and Bial. NLA: has received honoraria for educational presentations and advice service by Abbvie, Italfarmaco, Zambon, and Bial. IG: has received research support from Abbvie and Zambon and has served as a consultant for Abbvie, Exelts, and Zambon. JRM: has received honoraria for educational presentations, attending medical conferences, and advice service by Abbvie, UCB Pharma, Zam-bon, Italfarmaco, Bial, and Teva. MTB: none. CO: none. CV: has received honoraria for educational services from Zambon, Abbvie and UCB. VP: has served as consultant for Abbvie and Zambon; has received grant/research from Abbvie. MK: has received honoraria from Bial, the Spanish Neurology Society, and the International and Movement Disorders Society. MBE: has received honoraria for educational presentations and advice service by Abbvie, Abbott, UCB Pharma, Allergan, Zambon, Bial, and Qualigen. PMM: has received honoraria from Bial for lecturing in course and from the Parkinson and Movement Disorder Society (MDS) for management of the COA International Program of the Society. PM: has received honoraria from AbbVie, Abbott, Allergan, Bial, Merz, UCB, and Zambon and have received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Subdirección General de Evaluación y Fomento de la Investigación) and by Fondo Europeo de Desarrollo Regional (FEDER), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0437–2012, PI-0471–2013], the Sociedad Andaluza de Neurología, the Jacques and Gloria Gossweiler Foundation, the Fundación Alicia Koplowitz, the Fundación Mutua Madrileña. DSG: has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, Italfarmaco, Teva, Archímedes, Esteve, Stada, Merz, and grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017–2020 por el proyecto “PROGRESIÓN NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”; Concesión de Contrato para la intensificación de la actividad investigadora en el Sistema Nacional de Salud, Convocatoria 2021, Instituto de Salud Carlos III). CSG: none. JK: (1) Consulting fees: Roche, Zambon; (2) Stock / allotment: No; (3) Patent royalties / licensing fees: No; (4) Honoraria (e.g. lecture fees): Zambon, Teva, Bial, UCB; (5) Fees for promotional materials: No; (6) Research funding: Roche, Zambon, Ciberned; Instituto de Salud Carlos III; Fundació La Marató de TV3; (7) Scholarship from corporation: No; (8) Corporate laboratory funding: No; (9) Others (e.g. trips, travel, or gifts): No., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC

  • García-González, Pablo
  • Díaz Belloso, Rafael
  • Munoz-Delgado, Laura
  • Buiza Rueda, Dolores
  • Gómez-Garre, Pilar
  • Pérez-Tur, Jordi
  • Real, Luis M.
  • Bullido, María Jesús
  • Ruiz, Agustín
18 páginas, 2 figuras, Progressive supranuclear palsy (PSP) is a rare 4-repeat tauopathy that causes behavioural, movement and cognitive abnormalities. We genotyped all available clinical and histopathological PSP cases in Spain and Portugal (N = 522), and conducted the largest PSP GWAS of the Iberian population to date. Genetic burden analysis revealed reduced diagnostic specificity in clinically diagnosed atypical PSP cases-when applying the 2017 MDS criteria-compared to Richardson's syndrome cases. We independently replicated eight PSP risk variants in seven known loci (MAPT, MOBP, EIF2AK3, STX6, SLCO1A2, DUSP10 and APOE), and identified a novel locus in NFASC/CNTN2 (rs12744678 C: OR[95%CI] = 0.83[0.78-0.89]; p = 4.15·10-08) after meta-analysis with a newly available Dutch cohort and publicly available summary statistics (3,099 PSP; 11,482 controls). Enrichment analysis and protein expression profiling highlighted oligodendrocyte function and myelination as likely contributors to PSP pathogenesis. Our findings broaden the genetic landscape of PSP and suggest potential therapeutic avenues focused on modulating neuron-oligodendrocyte interactions., This work was funded by CIBERNED (Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas) 10th internal call for cooperative projects (Register number: 2019/09). Agustín Ruiz, Pascual Sanchez-Juan, Alberto Rábano, and Maria J. Bullido received funding from this convocatory. Pablo García-González received support by CIBERNED employment plan CNV-304-PRF-866. CIBERNED is integrated into ISCIII (Instituto de Salud Carlos III). Mercé Boada, Marta Marquié and Agustín Ruiz are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PI19/00335 and PI22/011403, and CIBERNED grant 2019/08. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE, and CIBERNED. Acción Estratégica en Salud is integrated into the Spanish National R  +  D  +  I Plan and funded by ISCIII—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”). Agustín Ruiz is supported by ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). He is also supported by the STAR Award. University of Texas System. Tx, United States, The South Texas ADRC. National Institute of Aging. National Institutes of Health. USA. (P30AG066546), the Keith M. Orme and Pat Vigeon Orme Endowed Chair in Alzheimer’s and Neurodegenerative Diseases (2024-2025) and Patricia Ruth Frederick Distinguished Chair for Precision Therapeutics in Alzheimer’s and Neurodegenerative Diseases (2025-2028). The genotyping service to generate GR@ACE and PSP/DEGESCO GWAS data was carried out at CEGEN-PRB3-ISCIII; it is supported by grant PT17/0019, of the PE I + D + i 2013-2016, funded by ISCIII and ERDF”. Itziar de Rojas received support by a national grant from ISCIII FI20/00215. Amanda Cano acknowledges the support of the Spanish Ministry of Science, Innovation and Universities under the grant Juan de la Cierva (FJC2018-036012-I), the support of ISCIII under the grant Sara Borrell (CD22/00125), Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00, and Fundación ADEY under the program “Proyectos de Investigación en Salud 2023”. Fondo de Investigacion en Salud (Instituto Carlos III) (PI17/00096) in the frame of the European Regional Development Fund (ERDF) and to Fundacio ́ la Marato ́ de TV3 (PI043296 and 202009-10). This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685, PY20_00896), and the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019). Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048-2017) from Andalusian Regional Ministry of Health. Laura Muñoz-Delgado was supported by the “Río Hortega” program [CM21/00051] from the Instituto de Salud Carlos III (ISCIII-FEDER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Sven J. van der Lee was funded for this study by NWO (#733050512, PROMO-GENODE: a PROspective study of MOnoGEnic causes Of Dementia) a substantial donation by Edwin Bouw Fonds and Dioraphte. SvdL further received funding for the GeneMINDS consortium, which is powered by Health~Holland, Top Sector Life Sciences & Health. Sven J. van der Lee is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. ABOARD also receives funding from de Hersenstichting, Edwin Bouw Fonds and Gieskes-Strijbisfonds. Array genotyping was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). This work has been supported by the Queen Sofia Foundation. Pascual Sánchez-Juan is supported by grants from ISCIII (PMP22/00022 and PI20/01011) and TED2021-131676B-100. Luis Miguel Real received support from “The absence of seroconversion after exposition to hepatitis C virus is not related to KIR-HLA genotype combinations” (GEHEP-012 study). Consejería de Salud de la Junta de Andalucía (grant number PI-0001/2017) and CIBERINFEC -Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas- Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación y Unión Europea (Spain) (NextGeneration EU) (grant number CB21/13/00118). Jose Luis Royo received support from Project 23.04.2021 from Santángela Foundation (Sevilla, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Dysphagia in Parkinson´s disease. A 5-year follow-up study

  • Santos-García, Diego
  • Deus Fonticoba, Teresa de
  • Jesús, Silvia
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria
  • Legarda, Inés
  • Hernández Vara, Jorge
  • Cabo, Iria
  • López Manzanares, Lydia
  • González Aramburu, Isabel
  • Ávila Rivera, Maria A.
  • Gómez Mayordomo, Víctor
  • Nogueira, Víctor
  • Dotor, Julio
  • Borrué, Carmen
  • Solano Vila, Berta
  • Álvarez Sauco, María
  • Vela, Lydia
  • Escalante, Sonia
  • Cubo, Esther
  • Mendoza, Zebenzui
  • Pareés, Isabel
  • Sánchez Alonso, Pilar
  • Alonso Losada, María G.
  • López-Ariztegui, Nuria
  • Gastón, Itziar
  • Kulisevsky, Jaime
  • Seijo, Manuel
  • Valero, Caridad
  • Alonso Redondo, Rubén
  • Ordás, Carlos
  • Menéndez-González, Manuel
  • McAfee, Darrian
  • Martínez-Martín, Pablo
  • Mir, Pablo
  • COPPADIS Study Group
COPPADIS Study Group: A. D. Adarmes, M. Almeria, M. G. Alonso Losada, A. Alonso Cánovas, F. Alonso Frech, R. Alonso Redondo, I. Álvarez, M. Álvarez Sauco, A. Aneiros Díaz, S. Arnáiz, S. Arribas, A. Ascunce Vidondo, M. Aguilar, M. A. Ávila, N. Bernardo Lambrich, H. Bejr-Kasem, M. Blázquez Estrada, M. Botí, C. Borrue, M. T. Buongiorno, C. Cabello González, I. Cabo López, N. Caballol, A. Cámara Lorenzo, H. Canfield Medina, E. Carabajal Pendón, F. Carrillo, F. J. Carrillo Padilla, E. Casas, M. J. Catalán, P. Clavero, A. Cortina Fernández, M. Cosgaya, A. Cots Foraster, A. Crespo Cuevas, E. Cubo, T. de Deus Fonticoba, O. de Fábregues-Boixar, M. Díez-Fairen, J. Dotor García-Soto, E. Erro, S. Escalante, E. Estelrich Peyret, N. Fernández Guillán, P. Gámez, M. Gallego, J. García Caldentey, C. García Campos, C. García Díez, J. M. García Moreno, I. Gastón, M. P. Gómez Garre, V. Gómez Mayordomo, J. González Aloy, I. González-Aramburu, J. González Ardura, B. González García, M. J. González Palmás, G. R. González Toledo, A. Golpe Díaz, M. Grau Solá, G. Guardia, J. Hernández Vara, A. Horta-Barba, D. Idoate Calderón, J. Infante, S. Jesús, J. Kulisevsky, M. Kurtis, C. Labandeira, M. A. Labrador, F. Lacruz, M. Lage Castro, S. Lastres Gómez, I. Legarda, N. López Ariztegui, L. M. López Díaz, D. López Domínguez, L. López Manzanares, B. López Seoane, S. del Lucas Pozo, Y. Macías, M. Mata, G. Martí Andres, M. J. Martí, J. C. Martínez Castrillo, P. Martinez-Martin, D. McAfee, M. T. Meitín, Z. Mendoza Plasencia, M. Menéndez González, C. Méndez del Barrio, P. Mir, J. Miranda Santiago, M. I. Morales Casado, A. Moreno Diéguez, I. Muro García, V. Nogueira, A. Novo Amado, S. Novo Ponte, C. Ordás, J. Pagonabarraga, I. Pareés, B. Pascual-Sedano, P. Pastor, A. Pérez Fuertes, R. Pérez Noguera, A. Planas-Ballvé, L. Planellas, M. A. Prats, C. Prieto Jurczynska, V. Puente, M. Pueyo Morlans, A. Puig Daví, N. Redondo Rafales, L. Rodríguez Méndez, A. B. Rodríguez Pérez, F. Roldán, M. Ruíz De Arcos, J. Ruíz Martínez, P. Sánchez Alonso, M. Sánchez-Carpintero, G. Sánchez Díez, A. Sánchez Rodríguez, P. Santacruz, D. Santos García, J. C. Segundo Rodríguez, M. Seijo, M. Sierra Peña, B. Solano Vila, E. Suárez Castro, J. P. Tartari, C. Valero, L. Vargas, L. Vela, C. Villanueva & B. Vives., [Background and objective] Dysphagia at time of diagnosis suggests atypical parkinsonism instead Parkinson´s disease (PD). Our aim was to analyze the frequency of dysphagia in patients with early PD comparing with a control group and to identify related factors., [Patients and methods] Patients with early PD (≤ 2 years from symptoms onset) who were recruited from January/2016 to November/2017 (baseline visit; V0) and evaluated annually for 5 years from the Spanish cohort COPPADIS were included in this prospective study. Controls were assessed at baseline and at 2-, 4-, and 5-year follow-up. Dysphagia was defined as a score ≥ 1 in the item 20 of the Non-Motor Symptoms Scale (NMSS)., COPPADIS and the present study were developed with the help of Fundación Española de Ayuda a la Investigación en Enfermedades Neurodegenerativas y/o de Origen Genético (https://fundaciondegen.org/) and Alpha Bioresearch (http://www.alphabioresearch.com). Also, we received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017–2020 por el Proyecto “PROGRESIÓN NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”) to develop a part of the COPPADIS project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Association of Physical Exercise With Structural Brain Changes and Cognitive Decline in Patients With Early Parkinson Disease

  • Diaz-Galván, Patricia
  • Franco-Rosado, Pablo
  • Silva-Rodríguez, Jesús
  • Castro-Labrador, Sandra
  • Labrador, Miguel Ángel
  • Muñoz-Delgado, Laura
  • Grothe, Michel J.
  • Mir, Pablo
[Data Availability] All clinical data and raw MRI scans used in this study are available in the PPMI database.30 The identity (ID) numbers of the participants included in this study, the MRI data before processing, and R scripts for statistical analyses in this study will be made available on request to facilitate replication of the findings., [Background and Objectives] Accumulating evidence suggests that physical activity is associated with a better clinical and cognitive course in Parkinson disease (PD), yet whether these effects are subserved by structural brain alterations are largely unexplored. The aim of this study was to investigate whether regular physical activity associates with a reduced longitudinal rate of neurodegeneration and slower cognitive decline in PD., [Methods] In this longitudinal, observational cohort study, we used data from the Parkinson's Progression Markers Initiative. We included patients with early PD who had serial assessments of regular physical activity, measured using the Physical Activity Scale for the Elderly, along with serial MRI scans from at least 2 time points over 4 years of follow-up. Regional cortical thickness and subcortical volumes were calculated using established procedures. We used multivariate linear mixed-effects models to analyze the effect of regular physical activity on the progression of MRI parameters over time. We further used mediation models with nonparametric bootstrap to test mediation effects of longitudinal structural brain changes on the association between regular physical activity and longitudinal cognitive functioning., [Results] A total of 120 patients with early PD were included (mean [SD] age = 60.8 [9.3] years; 33% women). Average regular physical activity levels over time were significantly associated with slower cortical thinning in temporoparietal cortical regions, including the lateral temporal cortex, the fusiform gyrus, the parahippocampal gyrus, and the inferior parietal cortex (p < 0.05). Regular physical activity levels over time were also associated with slower volume loss in the hippocampus and the amygdala (p < 0.05). The association of regular physical activity with slower decline in memory and attention functions was mediated by slower decreases in temporoparietal cortical thickness (βPASE-HVLT, = 0.06, p = 0.050; βPASE-SDMT = 0.04, p = 0.017) and hippocampal volume (βPASE-SDMT = 0.03, p = 0.016)., [Discussion] Regular physical activity is associated with a slower rate of neurodegeneration in the temporoparietal cortex and limbic areas in PD, which contributes to preserved cognitive function and improved long-term outcomes. This supports regular physical activity as a key intervention to delay disease progression and improve quality of life in patients with PD., This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1), funded by the Instituto de Salud Carlos III and co-funded by the European Union (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704, PI23/00512); the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685); the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019); the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022); the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896, PY20_00903); and the Alicia Koplowitz Foundation. MJG is supported by the “Miguel Servet” program of the ISCIII-FEDER (CP19/00031)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

EEG changes induced by dopamine replacement therapy in Parkinson’s disease with impulse control disorders

  • Martín-Rodríguez, Juan Francisco
  • Iglesias Camacho, Elena
  • Gómez-Campos, Francisco Javier
  • Franco-Rosado, Pablo
  • Garrote-Espina, Lorena
  • Muñoz-Delgado, Laura
  • Jesús Maestre, Silvia
  • Macías García, Daniel
  • Adarmes-Gómez, Astrid
  • Carrillo, Fátima
  • Mir, Pablo
[Objectives] Impulse control disorders (ICDs) are a common complication in Parkinson’s disease (PD) patients undergoing dopaminergic therapy. Although neurophysiological markers of ICDs have been identified, the effect of dopaminergic therapy on these markers is not fully understood. This study investigates the effect of dopaminergic therapy on EEG oscillatory activity in PD patients with and without ICDs., [Methods] A total of 26 PD patients—14 with ICDs (PD + ICD) and 12 healthy controls (HC)—participated. EEG recordings were obtained during regular dopamine therapy (ON) and after overnight withdrawal (OFF). Spectral analysis assessed group differences in EEG activity and the effect of dopaminergic treatment, while correlations between neurophysiological parameters and impulsivity were analysed., [Results] Results showed increased theta power (4–7.5 Hz) in the fronto-central regions of PD+ICD patients in the OFF state compared to healthy controls. In the ON state, PD+ICD patients showed increased frontal high beta (21–30 Hz) and central alpha (8–12 Hz) activity. Frontal beta activity correlated with impulsivity, independent of treatment dose., [Conclusions] PD + ICD patients show distinct neurophysiological profiles influenced by dopaminergic treatment, highlighting the modulatory effect of therapy on EEG patterns in these patients., [Significance] This study highlights the modulatory effect of dopaminergic therapy on EEG oscillatory patterns in PD patients with ICDs., We are very grateful to the individuals who participated in this study. This work was supported by a Grant PID2021-127034OA-I00 funded by MCIN/AEI/10.13039/501100011033 and, by “ERDF A way of making Europe”, the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI22/01704), the Fundación Progreso y Salud (PI-0055-2014), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019), the Consejería de Transformacion Economica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00903), and the Fundacion Alicia Koplowitz. Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases (project ID 739510). L.M.D. and P.M.R. are members of the COST Action IMMUPARKNET (CA21117). D.M.G. was supported by the “Juan Rodés” program [JR22/00073] from the Instituto de Salud Carlos III (ISCIII-FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

HMGCR genetic variability in Parkinson's disease in a Spanish cohort: associations with lipid metabolism and early onset

  • Díaz-Belloso, Rafael
  • Martín Bórnez, Miguel
  • Macías García, Daniel
  • García-Díaz, Sergio
  • Bonilla-Toribio, Marta
  • Buiza-Rueda, Dolores
  • Pineda-Sánchez, Rocío
  • Muñoz-Delgado, Laura
  • Ojeda, Elena
  • Jesús, Silvia
  • Adarmes-Gómez, Astrid
  • Carrillo, Fátima
  • Mir, Pablo
  • Gómez-Garre, Pilar
Lipid metabolism has emerged as a key factor in the pathophysiology of Parkinson’s disease (PD). While 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis, has been implicated in neurodegenerative disorders, such as Alzheimer disease, its role in PD remains unexplored. Given the shared pathological features between these neurodegenerative disorders (such as lysosomal dysfunction and lipid dysregulation) we hypothesized that HMGCR genetic variability could influence PD susceptibility and/or phenotypic expression, particularly in early-onset cases (EOPD). Therefore, we performed targeted sequencing of HMGCR in 1162 Spanish PD patients and analyzed associations with PD risk or age at onset. Replication was attempted in 436 PD cases from Parkinson’s Progression Markers Initiative (PPMI). We identified 21 HMGCR variants, including a likely pathogenic variant affecting the splice site of exon 4 (c.278-1G > A) in a patient with early-onset PD (EOPD), rapid progression, and severe dyslipidemia. The rs5908 variant was significantly associated with EOPD in our cohort (OR = 2.22, p = 0.025). Further analysis revealed rs5908 is in linkage disequilibrium with rs115169875, an intronic variant with putative regulatory impact. Our findings nominate HMGCR as a candidate gene for PD development, particularly in early-onset cases. The metabolic profile of the c.278-1G > A carrier parallels GBA-associated PD, suggesting convergent lipid-lysosomal pathways in neurodegeneration. While cohort differences highlight population-specific genetic effects, these findings underscore the importance of lipid pathways in PD and the need to explore HMGCR’s role in PD subtypes with metabolic comorbidity., Funding for open access publishing: Universidad de Sevilla/CBUA. This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150–1), and funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, PI24/00632), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685, PY20_00896), and the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471–2013, PE-0210–2018, PI-0459–2018, PE-0186–2019). Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048–2017) from Andalusian Regional Ministry of Health. Rafael Díaz Belloso and Miguel Martín Bornez were supported by pre-doctoral contracts for training in health research (PFIS) from Instituto de Salud Carlos III, with grant numbers FI20/00173 and FI22/00226, respectively. Daniel Macías-García was supported by the “Juan Rodés” program (JR22/00073) from the Instituto de Salud Carlos III (ISCIII- FEDER). Laura Muñoz-Delgado was supported by the “Río Hortega” program (CM21/00051) from the Instituto de Salud Carlos III (ISCIII- FEDER). Sergio García Díaz was supported by a University Teacher Programme (FPU20/00723) from the Ministry of Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have no competing interests to declare that they are relevant to the content of this article., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

"Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease"

  • Muñoz-Delgado, Laura
  • Williams-Gray, Caroline H.
  • Garraux, Gaetan
  • Clemente, Diego
  • Öztop-Çakmak, Özgür
  • Greenland, Julia C.
  • Figueira, Inês
  • Machín-Díaz, Isabel
  • Pirovano, Elenamaria
  • Di Flora, Alessia
  • Tournerie, Clotilde
  • Papoutsopoulou, Stamatia
  • Ertan, Sibel
  • Mir, Pablo
  • Comi, Cristoforo
Growing evidence supports the importance of immune processes in Parkinson’s disease (PD). However, there is a need to improve the quality of observational clinical studies investigating the role of immunity in PD. In this context, an expert panel from the COST Action IMMUPARKNET (CA21117) aimed to develop guidance recommendations for conducting optimal immune profiling in PD. Firstly, criteria for inclusion and exclusion of participants, clinical data collection and participant stratification have been considered. Secondly, brain imaging of neuroinflammation has been reviewed. Finally, this review discusses sample collection, handling and storage of biological samples. In conclusion, this document aims to guide the scientific community in the optimal design of immune profiling studies in PD, so that we can generate robust and reliable data to advance our knowledge in this field., This publication is based upon work from COST Action CA21117, The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork [IMMUPARKNET], supported by COST (European Cooperation in Science and Technology) (www.cost.eu). Laura Muñoz-Delgado is financially supported by the “Juan Rodés” programme (JR23/00016) from the Instituto de Salud Carlos III and receives funding support from the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022). Caroline Williams-Grey receives financial support from the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the Cambridge Centre for Parkinson-Plus, and grant funding from the UKRI Medical Research Council (MR/W029235/1), Cure Parkinson’s, Parkinson’s UK, and the Rosetrees Trust. Gaetan Garraux is supported by ‘Fonds Rahier’, University of Liège and Fonds de la Recherche Scientifique (F.R.S.-FNRS) de Belgique. Gaëtan Garraux has also received support for travel or honorarium from AbbVie, Eurogenerics and Zambon. Diego Clemente has received funding support from Instituto de Salud Carlos III (PI18/00357, PI21/00302, PI24/00447, co-funded by the European Union, CIBERNED CB22/05/00016, “INVESTIGO” programme in the frame of the Plan para la Recuperación, Transformación y Resiliencia (European Union Next Generation funds), and EMD Serono R&D Agreement). Ines Figueira is supported by the the ERC—Grant No. 804229; through PeX—2022.02127.PTDC (PERCEPT) and through the R&D unit iNOVA4Health (LISBOA-01-0145-FEDER-007344; UIDB/04462/2020), and LS4FUTURE Associated Laboratory (LA/P/0087/2020).Pablo Mir has received financial support from the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704 and PI23/00512), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018 and PE-0186-2019), the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896). Pablo Mir has also received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Allergan, AbbVie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva and Zambon. Cristoforo Comi is supported by the AGING PROJECT—Department of Excellence—Università del Piemonte Orientale. Cristoforo Comi has received travel grants for meeting participation from Ecupharma, Bial and Novartis., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication

NR4A2 Mutations Can Cause Intellectual Disability and Language Impairment With Persistent Dystonia-Parkinsonism

  • Jesús, Silvia
  • Hinarejos, Isabel|||0000-0001-9548-4359
  • Carrillo, Fátima
  • Martínez-Rubio, Dolores
  • Macías-García, Daniel|||0000-0002-4822-1529
  • Sánchez-Monteagudo, Ana
  • Adarmes-Gómez, A.D.|||0000-0002-1337-9289
  • Lupo, Vincenzo|||0000-0002-3774-9854
  • Pérez-Dueñas, Belén|||0000-0002-4979-2788
  • Mir, Pablo|||0000-0003-1656-302X
  • Espinós, Carmen|||0000-0003-4435-1809
TheNR4A2/NURR1gene (MIM*601828) has recently been associated with autosomal-dominantearly-onset dystonia-parkinsonism with intellectual disability.1NR4A2codifies for a nuclear tran-scription factor and is expressed mainly in the substantia nigra, ventral tegmental area, and limbicareas.2To date, 14 different alterations inNR4A2have been described associated with variousclinical phenotypes, mainly with neurodevelopment disorders (table e-1, links.lww.com/NXG/A371). We describe here an interesting case suffering a persistent dystonia-parkinsonism syndrome(DPS) with motor tics, which expands the clinical phenotype ofNR4A2-associated DPS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MNCD, A New Tool for Classifying Parkinson's Disease in Daily Clinical Practice

  • Santos García, Diego|||0000-0002-3126-5111
  • Álvarez Sauco, María
  • Calopa, Matilde|||0000-0002-6943-3707
  • Carrillo, Fátima
  • Escamilla Sevilla, Francisco|||0000-0003-2149-2668
  • Freire, Eric
  • García Ramos, Rocío
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Gómez Esteban, Juan Carlos|||0000-0002-4697-3890
  • Legarda, Inés
  • Luquin, Maria-Rosario|||0000-0002-5594-1794
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Martínez-Torres, Irene|||0000-0003-3081-5836
  • Mir, Pablo|||0000-0003-1656-302X
  • Sesar Ignacio, Ángel
Background and objective : Parkinson's disease (PD) is a clinically heterogeneous disorder in which the symptoms and prognosis can be very different among patients. We propose a new simple classification to identify key symptoms and staging in PD. Patients and Methods : Sixteen movement disorders specialists from Spain participated in this project. The classification was consensually approved after a discussion and review process from June to October 2021. The TNM classification and the National Institutes of Health Stroke Scale (NIHSS) were considered as models in the design. Results : The classification was named MNCD and included 4 major axes: (1) motor symptoms; (2) non-motor symptoms; (3) cognition; (4) dependency for activities of daily living (ADL). Motor axis included 4 sub-axes: (1) motor fluctuations; (2) dyskinesia; (3) axial symptoms; (4) tremor. Four other sub-axes were included in the non-motor axis: (1) neuropsychiatric symptoms; (2) autonomic dysfunction; (3) sleep disturbances and fatigue; (4) pain and sensory disorders. According to the MNCD, 5 stages were considered, from stage 1 (no disabling motor or non-motor symptoms with normal cognition and independency for ADL) to 5 (dementia and dependency for basic ADL). Conclusions : A new simple classification of PD is proposed. The MNCD classification includes 4 major axes and 5 stages to identify key symptoms and monitor the evolution of the disease in patients with PD. It is necessary to apply this proof of concept in a properly designed study.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life

  • Santos García, Diego|||0000-0002-3126-5111
  • de Deus Fonticoba, Teresa
  • Paz González, José M.
  • Cores Bartolomé, Carlos|||0000-0002-8352-2263
  • Valdés Aymerich, Lorena
  • Muñoz Enríquez, J. G.
  • Suárez Castro, Ester
  • Jesús, Silvia
  • Aguilar Barberà, Miquel
  • Pastor, Pau|||0000-0002-7493-8777
  • Planellas, Lluis|||0000-0002-0769-6675
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • López Manzanares, Lydia|||0000-0003-4615-4542
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Ávila, Asunción|||0000-0001-8357-0751
  • Catalán Alonso, Maria José
  • Nogueira, Víctor
  • Puente, Víctor
  • García Moreno, José Manuel
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Carrillo Padilla, Francisco
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, Maria G.
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Gastón, Itziar
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Seijo, Manuel
  • Ruiz Martínez, Javier|||0000-0001-7326-6270
  • Valero, Caridad
  • Kurtis, Mónica|||0000-0003-3037-9712
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • González Ardura, Jessica
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • López Díaz, Luis M.
  • Mir, Pablo|||0000-0003-1656-302X
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Coppadis Study Group, None
In a degenerative disorder such as Parkinson's disease (PD), it is important to establish clinical stages that allow to know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr's motor stage (H&Y) and the nonmotor symptoms burden (NMSB) (assessed by the nonmotor symptoms scale (NMSS)) provides information about the disability and the patient's quality of life (QoL) with regard to a defined clinical stage. Cross-sectional study in which 603 PD patients from the COPPADIS cohort were classified according to H&Y (1, stage I; 2, stage II; 3, stage III; 4, stage IV/V) and NMSB (A: NMSS = 0-20; B: NMSS = 21-40; C: NMSS = 41-70; D: NMSS ≥ 71) in 16 stages (HY.NMSB, from 1A to 4D). QoL was assessed with the PDQ-39SI, PQ-10, and EUROHIS-QOL8 and disability with the Schwab&England ADL (Activities of Daily Living) scale. A worse QoL and greater disability were observed at a higher stage of H&Y and NMSB (p < 0.0001). Combining both (HY.NMSB), patients in stages 1C and 1D and 2C and 2D had significantly worse QoL and/or less autonomy for ADL than those in stages 2A and 2B and 3A and 3B, respectively (p < 0.005; e.g., PDQ-39SI in 1D [ n = 15] vs 2A [ n = 101]: 28.6 ± 17.1 vs 7.9 ± 5.8; p < 0.0001). The HY.NMSB scale is simple and reflects the degree of patient involvement more accurately than the H&Y. Patients with a lower H&Y stage may be more affected if they have a greater NMS burden.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Predictors of clinically significant quality of life impairment in Parkinson's disease

  • Santos García, Diego|||0000-0002-3126-5111
  • de Deus Fonticoba, Teresa
  • Cores Bartolomé, Carlos|||0000-0002-8352-2263
  • Muñoz, Guillermo
  • Paz González, José M.
  • Martínez Miró, Cristina|||0000-0003-3968-5441
  • Suárez, Ester
  • Jesús, Silvia
  • Aguilar Barberà, Miquel
  • Pastor, Pau|||0000-0002-7493-8777
  • Planellas, Lluis|||0000-0002-0769-6675
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • López Manzanares, Luis
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Ávila, Asunción|||0000-0001-8357-0751
  • Catalán, Maria J.
  • Nogueira, Víctor
  • Puente, Víctor
  • Ruíz de Arcos, María
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Carrillo Padilla, Francisco
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, Maria G.
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Gastón, Itziar
  • Clavero, Pedro
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Seijo, Manuel
  • Rúiz Martínez, Javier
  • Valero, Caridad
  • Kurtis, Mónica|||0000-0003-3037-9712
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • González Ardura, Jessica
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • López Díaz, Luis M.
  • McAfee, Darrian
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Mir, Pablo|||0000-0003-1656-302X
  • Adarmes-Gómez, A.D.|||0000-0002-1337-9289
  • Almeria, Marta|||0000-0001-7445-6113
  • Alonso-Cánovas, Araceli|||0000-0003-1702-2655
  • Alonso Frech, Fernando
  • Alonso Redondo, Ruben
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Aneiros Díaz, Ángel
  • Arnáiz, Sandra
  • Arribas, Sonia
  • Ascunce Vidondo, Arancha
  • Bernardo Lambrich, Noemí
  • Bejr-kasem, Helena|||0000-0001-8828-5976
  • Botí, M.|||0000-0003-2963-6929
  • Buongiorno, María Teresa
  • Cabello González, Carolina
  • Cámara, Ana|||0000-0002-8005-9461
  • Canfield Medina, H.
  • Carrillo, Fátima
  • Casas, Elena
  • Cortina Fernández, Ana
  • Cots-Foraster, Anna|||0000-0002-9169-7653
  • Crespo Cuevas, Ane Miren|||0000-0003-1400-5809
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Dotor García-Soto, Julio
  • Erro, Elena
  • Estelrich Peyret, Elena
  • Fernández Guillán, Noelia
  • Gámez, Pedro
  • Gallego, Miguel|||0000-0002-8882-4033
  • García Campos, Cristina|||0000-0003-3277-2374
  • García Moreno, José Manuel
  • Gómez Garre, Maria P.
  • Gómez Mayordomo, Víctor|||0000-0001-9343-8439
  • González Aloy, Javier
  • González García, Beatriz
  • González Palmás, María J.
  • González Toledo, G.R.
  • Gabriel, R.
  • Golpe Díaz, Ana
  • Grau Solá, Mireia
  • Guardia, Gemma
  • Horta-Barba, Andrea|||0000-0003-0050-5466
  • Idoate Calderón, Daniel
  • Infante, Jon|||0000-0003-4025-4606
  • Labandeira, Carmen
  • Labrador-Espinosa, Miguel A.|||0000-0003-3576-1777
  • Lacruz, Francisco
  • Lage Castro, Melva
  • Lastres Gómez, Sonia
  • López Seoane, Balbino
  • Lucas del Pozo, Sara
  • Macías, Yolanda
  • Mata, Marina|||0000-0001-9693-7663
  • Martí Andres, Gloria
  • Martí Domenech, Maria Josep|||0000-0002-9872-7835
  • Meitín, Maria T.
  • Menéndez González, Manuel
  • Méndez del Barrio, Carlota
  • Miranda Santiago, Javier
  • Morales Casado, María, I.
  • Moreno Diéguez, Antonio
  • Novo Amado, Alba
  • Novo Ponte, Sabela
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Pareés, Isabel|||0000-0002-6873-4823
  • Pascual Sedano, Berta María|||0000-0002-9298-8241
  • Pérez Fuertes, Aída
  • Pérez Noguera, Rafael
  • Planas-Ballvé, Anna|||0000-0002-8137-0622
  • Prats, Marian A.
  • Prieto Jurczynska, Cristina
  • Pueyo Morlans, Mercedes
  • Puig-Davi, Arnau|||0000-0001-8883-4947
  • Redondo Rafales, Nuria
  • Rodríguez Méndez, Luisa
  • Rodríguez Pérez, Amparo B.
  • Roldán, Florinda
  • Sánchez-Carpintero, Macarena
  • Sánchez Díez, Gemma
  • Sánchez Rodríguez, Antonio|||0000-0002-8266-1157
  • Santacruz, Pilar
  • Segundo Rodríguez, José C.
  • Sierra Peña, María
  • Tartari, Juan P.
  • Vargas, Laura
  • Villanueva, Clara
  • Vives-Pastor, Bárbara
  • Villar, María D.
Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease, Imaging results from the COPPADIS study

  • Grothe, Michel|||0000-0003-2600-9022
  • Labrador-Espinosa, Miguel A.|||0000-0003-3576-1777
  • Jesús Maestre, Silvia|||0000-0002-1874-4628
  • Macías-García, Daniel|||0000-0002-4822-1529
  • Adarmes-Gómez, A.D.|||0000-0002-1337-9289
  • Carrillo, Fátima
  • Iglesias Camacho, Elena
  • Franco-Rosado, Pablo
  • Roldán Lora, Florinda
  • Martín-Rodríguez, Juan Francisco|||0000-0003-1392-8775
  • Aguilar Barberà, Miquel
  • Pastor, Pau|||0000-0002-7493-8777
  • Escalante, Sonia|||0000-0001-8931-1400
  • Soriano Vila, Berta
  • Cots-Foraster, Anna|||0000-0002-9169-7653
  • Ruiz Martínez, Javier|||0000-0001-7326-6270
  • Carrillo Padilla, Francisco
  • Pueyo Morlans, Mercedes
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Infante Ceberio, Jon
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • de Deus Fonticoba, Teresa
  • Pascual Sedano, Berta María|||0000-0002-9298-8241
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Santos García, Diego|||0000-0002-3126-5111
  • Mir, Pablo|||0000-0003-1656-302X
Introduction: We aimed to assess associations between multimodal neuroimaging measures of cholinergic basal forebrain (CBF) integrity and cognition in Parkinson's disease (PD) without dementia. Methods: The study included a total of 180 non-demented PD patients and 45 healthy controls, who underwent structural MRI acquisitions and standardized neurocognitive assessment through the PD-Cognitive Rating Scale (PD-CRS) within the multicentric COPPADIS-2015 study. A subset of 73 patients also had Diffusion Tensor Imaging (DTI) acquisitions. Volumetric and microstructural (mean diffusivity, MD) indices of CBF degeneration were automatically extracted using a stereotactic CBF atlas. For comparison, we also assessed multimodal indices of hippocampal degeneration. Associations between imaging measures and cognitive performance were assessed using linear models. Results: Compared to controls, CBF volume was not significantly reduced in PD patients as a group. However, across PD patients lower CBF volume was significantly associated with lower global cognition (PD-CRS: r = 0.37, p < 0.001), and this association remained significant after controlling for several potential confounding variables (p = 0.004). Analysis of individual item scores showed that this association spanned executive and memory domains. No analogue cognition associations were observed for CBF MD. In covariate-controlled models, hippocampal volume was not associated with cognition in PD, but there was a significant association for hippocampal MD (p = 0.02). Conclusions: Early cognitive deficits in PD without dementia are more closely related to structural MRI measures of CBF degeneration than hippocampal degeneration. In our multicentric imaging acquisitions, DTI-based diffusion measures in the CBF were inferior to standard volumetric assessments for capturing cognition-relevant changes in non-demented PD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours, results from the COPPADIS cohort

  • Jesús, Silvia
  • Labrador-Espinosa, Miguel A.|||0000-0003-3576-1777
  • Adarmes-Gómez, A.D.|||0000-0002-1337-9289
  • Méndez-del Barrio, Carlota
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Alonso-Cánovas, Araceli|||0000-0003-1702-2655
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Novo-Ponte, Sabela
  • Alonso-Losada, Maria Gema
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Segundo Rodríguez, José C.
  • Morales, M.I.
  • Gastón, Itziar
  • Lacruz Bescos, Francisco
  • Clavero Ibarra, Pedro
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Pascual Sedano, Berta María|||0000-0002-9298-8241
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Santos García, Diego|||0000-0002-3126-5111
  • Mir, Pablo|||0000-0003-1656-302X
  • Aguilar Barberà, Miquel
  • Almeria, Marta|||0000-0001-7445-6113
  • Álvarez Sauco, María
  • Arnáiz, Sandra
  • Arribas, Sonia
  • Ascunce Vidondo, Arancha
  • Bernardo Lambrich, Noemí
  • Bejr-kasem, Helena|||0000-0001-8828-5976
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Botí, M.|||0000-0003-2963-6929
  • Borrué, Carmen
  • Cabello González, Carolina
  • Cámara, Ana|||0000-0002-8005-9461
  • Carrillo, Fátima
  • Carrillo Padilla, Francisco
  • Casas, Elena
  • Catalán Alonso, Maria José
  • Cortina Fernández, Ana
  • Cots-Foraster, Anna|||0000-0002-9169-7653
  • Crespo Cuevas, Ane Miren|||0000-0003-1400-5809
  • Cubo, Esther|||0000-0003-0018-1182
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Escalante, Sonia|||0000-0001-8931-1400
  • Erro, Elena
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • Fernández Guillán, Noelia
  • Gámez, Pedro
  • Gallego, Miguel|||0000-0002-8882-4033
  • García Caldentey, Juan
  • García Campos, Cristina|||0000-0003-3277-2374
  • García Moreno, José Manuel
  • Gómez Garre, María P.
  • González Aloy, Javier
  • González Ardura, Jessica
  • González García, Beatriz
  • González Palmás, María J.
  • González Toledo, G.R.
  • Golpe Díaz, Ana
  • Grau Solá, Mireia
  • Guardia, Gemma
  • Horta-Barba, Andrea|||0000-0003-0050-5466
  • Infante, Jon|||0000-0003-4025-4606
  • Kurtis, Mónica|||0000-0003-3037-9712
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Labandeira, Carmen
  • Lage Castro, Melva
  • Legarda, Inés
  • López Díaz, Luis M.
  • López Manzanares, Lydia|||0000-0003-4615-4542
  • López Seoane, Balbino
  • Macías, Yolanda
  • Mata, Marina|||0000-0001-9693-7663
  • Martí Andres, Gloria
  • Martí, María J.
  • McAfee, Darrian
  • Meitín, Maria T.
  • Menéndez González, Manuel
  • Miranda Santiago, Javier
  • Moreno Diéguez, Antonio
  • Nogueira, Víctor
  • Novo Amado, Alba
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • Pastor, Pau|||0000-0002-7493-8777
  • Paz González, José M.
  • Pareés, Isabel|||0000-0002-6873-4823
  • Pérez Fuertes, Aída
  • Pérez Noguera, Rafael
  • Planellas, Lluis|||0000-0002-0769-6675
  • Prats, M. A.
  • Prieto Jurczynska, Cristina
  • Pueyo Morlans, Mercedes
  • Puente, Víctor
  • Redondo Rafales, Nuria
  • Rodríguez Méndez, Luisa
  • Rodríguez Pérez, A. B.
  • Roldán, Florinda
  • De Arcos, M.R.
  • Ruíz Martínez, J.
  • Sánchez-Carpintero, Macarena
  • Sánchez Díez, Gemma
  • Sánchez Rodríguez, Antonio|||0000-0002-8266-1157
  • Santacruz, Pilar
  • Seijo, Manuel
  • Serarols, A.
  • Sierra Peña, María
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Suárez Castro, Ester
  • Tartari, Juan Pablo
  • Valero, Caridad
  • Vargas, Laura
  • Vázquez Gómez, R.
  • Vela, Lydia|||0000-0001-6663-395X
  • Villanueva, Clara
  • Vives-Pastor, Bárbara
  • Villar, Maria Dolores
The study was aimed at analysing the frequency of impulse control disorders (ICDs) and compulsive behaviours (CBs) in patients with Parkinson's disease (PD) and in control subjects (CS) as well as the relationship between ICDs/CBs and motor, nonmotor features and dopaminergic treatment in PD patients. Data came from COPPADIS-2015, an observational, descriptive, nationwide (Spain) study. We used the validated Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) for ICD/CB screening. The association between demographic data and ICDs/CBs was analyzed in both groups. In PD, this relationship was evaluated using clinical features and treatment-related data. As result, 613 PD patients (mean age 62.47 ± 9.09 years, 59.87% men) and 179 CS (mean age 60.84 ± 8.33 years, 47.48% men) were included. ICDs and CBs were more frequent in PD (ICDs 12.7% vs. 1.6%, p < 0.001; CBs 7.18% vs. 1.67%, p = 0.01). PD patients had more frequent previous ICDs history, premorbid impulsive personality and antidepressant treatment (p < 0.05) compared with CS. In PD, patients with ICDs/CBs presented younger age at disease onset, more frequent history of previous ICDs and premorbid personality (p < 0.05), as well as higher comorbidity with nonmotor symptoms, including depression and poor quality of life. Treatment with dopamine agonists increased the risk of ICDs/CBs, being dose dependent (p < 0.05). As conclusions, ICDs and CBs were more frequent in patients with PD than in CS. More nonmotor symptoms were present in patients with PD who had ICDs/CBs compared with those without. Dopamine agonists have a prominent effect on ICDs/CBs, which could be influenced by dose.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Motor Fluctuations Development Is Associated with Non-Mostor Symptoms Burden Progression in Parkinson's Disease Patients, A 2-Year Follow-Up Study

  • Santos García, Diego|||0000-0002-3126-5111
  • de Deus Fonticoba, Teresa
  • Cores Bartolomé, Carlos|||0000-0002-8352-2263
  • Feal Painceiras, Maria J.
  • Suárez Castro, Ester
  • Canfield Medina, H.
  • Martínez Miró, Cristina|||0000-0003-3968-5441
  • Jesús, Silvia
  • Aguilar Barberà, Miquel
  • Pastor, Pau|||0000-0002-7493-8777
  • Planellas, Lluis|||0000-0002-0769-6675
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • López Manzanares, Lydia|||0000-0003-4615-4542
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Ávila Rivera, Maria A.
  • Gómez Mayordomo, Víctor|||0000-0001-9343-8439
  • Nogueira, Víctor
  • Puente, Víctor
  • Dotor García-Soto, Julio
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Carrillo Padilla, Francisco
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, Maria G.
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Gastón, Itziar
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Seijo, Manuel
  • Ruiz Martínez, Javier|||0000-0001-7326-6270
  • Valero, Caridad
  • Kurtis, Mónica|||0000-0003-3037-9712
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • González Ardura, Jessica
  • Alonso Redondo, Ruben
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • López Díaz, Luis M.
  • McAfee, Darrian
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Mir, Pablo|||0000-0003-1656-302X
  • Santacruz, Pilar
  • Pascual Sedano, Berta María|||0000-0002-9298-8241
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Martí Domenech, Maria Josep|||0000-0002-9872-7835
  • Martí-Andres, Gloria|||0000-0001-6474-8454
  • Lucas-del-Pozo, Sara|||0000-0002-5431-8204
  • Horta-Barba, Andrea|||0000-0003-0050-5466
  • Crespo Cuevas, Ane Miren|||0000-0003-1400-5809
  • Cámara, Ana|||0000-0002-8005-9461
  • Bejr-kasem, Helena|||0000-0001-8828-5976
The aim of the present study was to analyze the progression of non-motor symptoms (NMS) burden in Parkinson's disease (PD) patients regarding the development of motor fluctuations (MF). PD patients without MF at baseline, who were recruited from January 2016 to November 2017 (V0) and evaluated again at a 2-year follow-up (V2) from 35 centers of Spain from the COPPADIS cohort, were included in this analysis. MF development at V2 was defined as a score ≥ 1 in the item-39 of the UPDRS-Part IV, whereas NMS burden was defined according to the Non-motor Symptoms Scale (NMSS) total score. Three hundred and thirty PD patients (62.67 ± 8.7 years old; 58.8% males) were included. From V0 to V2, 27.6% of the patients developed MF. The mean NMSS total score at baseline was higher in those patients who developed MF after the 2-year follow-up (46.34 ± 36.48 vs. 34.3 ± 29.07; p = 0.001). A greater increase in the NMSS total score from V0 to V2 was observed in patients who developed MF (+16.07 ± 37.37) compared to those who did not develop MF (+6.2 ± 25.8) (p = 0.021). Development of MF after a 2-year follow-up was associated with an increase in the NMSS total score (β = 0.128; p = 0.046) after adjustment to age, gender, years from symptoms onset, levodopa equivalent daily dose (LEDD) and the NMSS total score at baseline, and the change in LEDD from V0 to V2. In PD patients, the development of MF is associated with a greater increase in the NMS burden after a 2-year follow-up.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life

  • Santos García, Diego|||0000-0002-3126-5111
  • de Deus Fonticoba, Teresa
  • Cores Bartolomé, Carlos|||0000-0002-8352-2263
  • Feal Painceiras, Maria J.
  • Íñiguez Alvarado, María Cristina
  • García Díaz, Iago|||0000-0003-3304-0714
  • Jesús, Silvia
  • Buongiorno, Maria Teresa
  • Planellas, Lluis|||0000-0002-0769-6675
  • Cosgaya, Marina
  • García Caldentey, Juan
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • López Manzanares, Lydia|||0000-0003-4615-4542
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Ávila Rivera, Maria A.
  • Gómez Mayordomo, Víctor|||0000-0001-9343-8439
  • Nogueira, Víctor
  • Puente, Víctor
  • Dotor García-Soto, Julio
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Carrillo Padilla, Francisco
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, Maria G.
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Gastón, Itziar
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Mendez-Gonzalez, Manuel|||0000-0002-5218-0774
  • Seijo, Manuel
  • Ruiz Martínez, Javier|||0000-0001-7326-6270
  • Valero, Caridad
  • Kurtis, Mónica|||0000-0003-3037-9712
  • González Ardura, Jessica
  • Alonso Redondo, Ruben
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • López Díaz, Luis M.
  • McAfee, Darrian
  • Calopa, Matilde|||0000-0002-6943-3707
  • Carrillo, Fátima
  • Escamilla Sevilla, Francisco|||0000-0003-2149-2668
  • Freire-Alvarez, Eric|||0000-0002-1748-0325
  • Gómez Esteban, Juan Carlos|||0000-0002-4697-3890
  • García-Ramos, Rocío|||0000-0003-0386-8940
  • Luquin, Maria-Rosario|||0000-0002-5594-1794
  • Martínez-Torres, Irene|||0000-0003-3081-5836
  • Sesar Ignacio, Ángel
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Mir, Pablo|||0000-0003-1656-302X
Recently, a novel simple classification called MNCD, based on 4 axes (Motor; Non-motor; Cognition; Dependency) and 5 stages, has been proposed to classify Parkinson's disease (PD). Our aim was to apply the MNCD classification in a cohort of PD patients for the first time and also to analyze the correlation with quality of life (QoL) and disease severity. Data from the baseline visit of PD patients recruited from 35 centers in Spain from the COPPADIS cohort fromJanuary 2016 to November 2017 were used to apply the MNCD classification. Three instruments were used to assess QoL:1) the 39-item Parkinson's disease Questionnaire [PDQ-39]); PQ-10; the EUROHIS-QOL 8-item index (EUROHIS-QOL8). Four hundred and thirty-nine PD patients (62.05±7.84 years old; 59% males) were included. MNCD stage was:stage 1, 8.4% (N = 37); stage 2, 62% (N = 272); stage 3, 28.2% (N = 124); stage 4-5, 1.4% (N = 6). A more advancedMNCD stage was associated with a higher score on the PDQ39SI (p < 0.0001) and a lower score on the PQ-10 (p< 0.0001) and EUROHIS-QOL8 (p< 0.0001). In many other aspects of the disease, such as disease duration, levodopa equivalent daily dose, motor symptoms, non-motor symptoms, and autonomy for activities of daily living, an association between the stage and severity was observed, with data indicating a progressive worsening related to disease progression throughout the proposed stages. Staging PD according to the MNCD classification correlated with QoL and disease severity. The MNCD could be a proper tool to monitor the progression of PD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden

  • Santos García, Diego|||0000-0002-3126-5111
  • de Deus Fonticoba, Teresa
  • Cores Bartolomé, Carlos|||0000-0002-8352-2263
  • Feal Painceiras, Maria J.
  • García Díaz, Iago|||0000-0003-3304-0714
  • Íñiguez Alvarado, María Cristina
  • Paz, Jose Manuel
  • Jesús, Silvia
  • Cosgaya, Marina
  • Garcia Caldentey, Juan
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • López Manzanares, Lydia|||0000-0003-4615-4542
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Ávila Rivera, Maria A.
  • Gómez Mayordomo, Victor
  • Nogueira, Victor
  • Dotor García-Soto, Julio
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Mendoza, Zebenzui
  • Martínez Castrillo, Juan C.
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, Maria G.
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Gastón, Itziar
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Seijo, Manuel
  • Valero, Caridad
  • Alonso Redondo, Ruben
  • Buongiorno, Maria Teresa
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • Mendez-Gonzalez, Manuel|||0000-0002-5218-0774
  • McAfee, Darrian
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Mir, Pablo|||0000-0003-1656-302X
Recently, we demonstrated that staging Parkinson's disease (PD) with a novel simple classification called MNCD, based on four axes (motor, non-motor, cognition, and dependency) and five stages, correlated with disease severity and patients' quality of life. Here, we analyzed the correlation of MNCD staging with PD caregiver's status. Data from the baseline visit of PD patients and their principal caregiver recruited from 35 centers in Spain from the COPPADIS cohort from January 2016 to November 2017 were used to apply the MNCD total score (from 0 to 12) and MNCD stages (from 1 to 5) in this cross-sectional analysis. Caregivers completed the Zarit Caregiver Burden Inventory (ZCBI), Caregiver Strain Index (CSI), Beck Depression Inventory-II (BDI-II), PQ-10, and EUROHIS-QOL 8-item index (EUROHIS-QOL8). Two hundred and twenty-four PD patients (63 ± 9.6 years old; 61.2% males) and their caregivers (58.5 ± 12.1 years old; 67.9% females) were included. The frequency of MNCD stages was 1, 7.6%; 2, 58.9%; 3, 31.3%; and 4-5, 2.2%. A more advanced MNCD stage was associated with a higher score on the ZCBI (p <.0001) and CSI (p <.0001), and a lower score on the PQ-10 (p =.001), but no significant differences were observed in the BDI-II (p =.310) and EUROHIS-QOL8 (p =.133). Moderate correlations were observed between the MNCD total score and the ZCBI (r =.496; p <.0001), CSI (r =.433; p <.0001), and BDI-II (r =.306; p <.0001) in caregivers. Staging PD according to the MNCD classification is correlated with caregivers' strain and burden.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Risk of Cognitive Impairment in Patients With Parkinson's Disease With Visual Hallucinations and Subjective Cognitive Complaints

  • Santos García, Diego|||0000-0002-3126-5111
  • de Deus Fonticoba, Teresa
  • Bartolomé, Carlos C.
  • Feal Painceiras, Maria J.
  • Paz González, Jose M.
  • Martinez Miró, Cristina
  • Jesús, Silvia
  • Aguilar Barberà, Miquel
  • Pastor, Pau|||0000-0002-7493-8777
  • Planellas, Lluis|||0000-0002-0769-6675
  • Cosgaya, Marina
  • Garcia Caldentey, Juan
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • Lopez Manzanares, Lydia
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Ávila Rivera, Maria A.
  • Gomez Mayordomo, Victor
  • Nogueira, Victor
  • Puente, Victor
  • Dotor García-Soto, Julio
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Carrillo Padilla, Francisco
  • Martinez Castrillo, Juan C.
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, M.G.
  • Lopez Ariztegui, Nuria
  • Gastón, Itziar
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Seijo, Manuel
  • Ruiz Martínez, Javier|||0000-0001-7326-6270
  • Valero, Caridad
  • Kurtis, Monica
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • González Ardura, Jessica
  • Alonso Redondo, Ruben
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • Lopez Diaz L., Luis M.
  • McAfee, Darrian
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Mir, Pablo|||0000-0003-1656-302X
  • Coppadis Study Group, None
Visual hallucinations (VH) and subjective cognitive complaints (SCC) are associated with cognitive impairment (CI) in Parkinson's disease. Our aims were to determine the association between VH and SCC and the risk of CI development in a cohort of patients with Parkinson's disease and normal cognition (PD-NC). Methods Patients with PD-NC (total score of.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prevalence and Factors Associated with Drooling in Parkinson's Disease, Results from a Longitudinal Prospective Cohort and Comparison with a Control Group

  • Santos García, Diego|||0000-0002-3126-5111
  • de Deus Fonticoba, Teresa
  • Cores Bartolomé, Carlos|||0000-0002-8352-2263
  • Feal Painceiras, M.J.
  • Íñiguez Alvarado, María Cristina
  • Jesús Maestre, Silvia|||0000-0002-1874-4628
  • Buongiorno, M.T.
  • Planellas, L.
  • Cosgaya, Marina
  • García Caldentey, J.
  • Caballol, Nuria|||0000-0003-3363-3077
  • Legarda, Inés
  • Hernández-Vara, Jorge|||0000-0002-9129-5224
  • Cabo-Lopez, Iria|||0000-0003-2436-6499
  • López Manzanares, L.
  • Gonzalez-Aramburu, Isabel|||0000-0002-3696-4093
  • Ávila Rivera, Maria A.
  • Gómez Mayordomo, V.
  • Nogueira, V.
  • Puente, Víctor
  • Dotor García-Soto, J.
  • Borrué, Carmen
  • Solano Vila, Berta|||0009-0007-8945-0487
  • Álvarez Sauco, María
  • Vela, Lydia|||0000-0001-6663-395X
  • Escalante, Sonia|||0000-0001-8931-1400
  • Cubo, Esther|||0000-0003-0018-1182
  • Carrillo Padilla, Francisco
  • Martínez-Castrillo, Juan Carlos|||0000-0001-7744-6850
  • Sánchez Alonso, Pilar|||0000-0003-0496-4707
  • Alonso Losada, M.G.
  • López Ariztegui, Nuria|||0000-0001-7172-3191
  • Gastón, I.
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Seijo, Manuel
  • Rúiz Martínez, J.
  • Valero Mayor, Cristina|||0000-0003-3397-2888
  • Kurtis, M.
  • Fàbregues-Boixar i Nebot, Oriol de|||0000-0002-3518-5338
  • González Ardura, J.
  • Alonso Redondo, R.
  • Ordás Bandera, Carlos Manuel|||0000-0003-3551-8769
  • López Díaz, L.M.L.
  • McAfee, D.
  • Martínez Martín, Pablo|||0000-0003-0837-5280
  • Mir, Pablo|||0000-0003-1656-302X
  • Coppadis, S.G.
Drooling in Parkinson's disease (PD) is frequent but often goes underrecognized. Our aim was to examine the prevalence of drooling in a PD cohort and compare it with a control group. Specifically, we identified factors associated with drooling and conducted subanalyses in a subgroup of very early PD patients. PD patients who were recruited from January 2016 to November 2017 (baseline visit; V0) and evaluated again at a 2-year ± 30-day follow-up (V2) from 35 centers in Spain from the COPPADIS cohort were included in this longitudinal prospective study. Subjects were classified as with or without drooling according to item 19 of the NMSS (Nonmotor Symptoms Scale) at V0, V1 (1-year ± 15 days), and V2 for patients and at V0 and V2 for controls. The frequency of drooling in PD patients was 40.1% (277/691) at V0 (2.4% (5/201) in controls; p < 0.0001), 43.7% (264/604) at V1, and 48.2% (242/502) at V2 (3.2% (4/124) in controls; p < 0.0001), with a period prevalence of 63.6% (306/481). Being older (OR = 1.032; p = 0.012), being male (OR = 2.333; p < 0.0001), having greater nonmotor symptom (NMS) burden at the baseline (NMSS total score at V0; OR = 1.020; p < 0.0001), and having a greater increase in the NMS burden from V0 to V2 (change in the NMSS total score from V0 to V2; OR = 1.012; p < 0.0001) were identified as independent predictors of drooling after the 2-year follow-up. Similar results were observed in the group of patients with ≤2 years since symptom onset, with a cumulative prevalence of 64.6% and a higher score on the UPDRS-III at V0 (OR = 1.121; p = 0.007) as a predictor of drooling at V2. Drooling is frequent in PD patients even at the initial onset of the disease and is associated with a greater motor severity and NMS burden.